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1. INTRODUCTION 
              The ancient Siddha system, a tradition presumed to be lost is now finding its 
way back into the hearts and lives of people worldwide. Ancient wisdom in its 
nativity remains conserved by the teaching imparted by sages in primordial times, 
even in our postmodern world.  
According to Siddha, 96 thathuvams influence the activities of the individual 
from birth to death. This system which also believes body- mind- spirit is inseparable, 
is always taken into consideration as a whole as their interconnectedness is a pre-
established cosmic design of existence. 
As the population increasing day by day there is an exponential increase and 
emergence of new diseases. The environment is getting more and more polluted, the 
humanity has almost come to a stage where the various available preventive measures 
are to be valued much well than the existing curative measures. Apart from 
Prevention and cure which exist in all systems, Siddha system in addition also 
believes strongly in the transcendental (immortality). 
As above quoted the birth of an individual is an auspicious moment, the child 
care starts before conception, siddha system believes that healthy state of the child 
depends on healthy being of both mother and father. According to World Health 
Organization (WHO) more than 80% of the world’s population relies on traditional 
practitioners and their armamentarium of medicinal plants (WHO 1980) in order to 
meet health care needs in spite of modern medicine which is well established 
worldwide. Over a period of time Siddha has changed a lot from gurukula system to 
University form, which has 6 branches one among is pediatrics, this branch has a 
major role to evolve the future healthy citizens.  
Even though siddha system has various branches till date, author of gleanings 
from siddha medicine quoted that Balavagadam (pediatrics) and alchemy & elixirs for 
longevity (Kapur, 2015) are the well defined branches which are still in practice. It is 
pertinent to mention here for the importance of Balavagadam, the approach is holistic 
than divisive.  
Siddha medicine deals formally and systematically with each medical subject 
and is usually describes in a poetic verse format so that the knowledge could be 
passed down orally over generations from siddha physicians to their disciples 
(Thambyayah, 2014). Similar to other Indian system of medicine siddha also follows 
mukkutram theory and states that psycho-biological aspect is governs by 3 mukkutram 
vali, azhal and iyam, any change in body is due to the imbalance in these 3 
mukkutrams (Natarajan,2009).  
2 
 
Anubhava vaidhya kalanjiyam a classical siddha text classifies the diseases of 
childhood into 108 diseases which further classified into various sub-types based on 
the change in nature of disease presentation. 
One of the pediatric disease maantham (maantham) which can be taken as 
anatomical malformation and physiological dysfunction. It has 21 types in which I 
have chosen the dissertation topic as kana maantham because of its frequent 
prevalence among the children. Kana maantham symptoms have both respiratory and 
gastrointestinal symptoms. It may be compared with pediatric disease Acute 
Gastroenteritis. Worldwide, gastroenteritis affects 3 to 5 billion children each year 
and accounts for 1.5 to 2.5 million deaths per year (Chung M Chow et al, 2010) in 
children fewer than five years of age. Over the past two decades, pediatric acute 
gastroenteritis has been the subject of considerable worldwide attention and effort. 
Optimal management with oral or intravenous fluids minimizes the risk of 
dehydration and its adverse outcomes. (Discipline of Pediatrics and Child Health 
2006)Routine use of antibiotics, antidiarrhoeal agents, and antiemetic is not 
recommended and may cause harm. In siddha there are numerous sastric formulations 
for pediatric disease which can control diarrhea very efficiently without any major 
adverse effect. 
Siddha literature describe a group of herbals suitable for pediatric population 
based on the pediatric organ developments, keeping  pharmacokinetic and 
pharmacodynamics in mind, which indicates the in depth knowledge of siddha 
medicinal system in pediatric diseases. One among the drug chosen for kana 
maantham is uthamani karukku.  
Here we go with the literature review of both siddha system and modern 
system to evaluate the correlation between its clinical signs and symptoms. The drug 
review is the very essential and noticeable part of the work. The drug has been 
undergone for preclinical screening, its pharmacological activities and toxic studies 
shows the efficient role of the drug and its safety, which is very important as it is 
administered to pediatric age group.  
Then the clinical trial starts with the selection of patients according to the 
clinical symptoms of kana maantham and the patients are provided with informed 
consent form and patient information sheet which explains detail about the study. 
Patient’s history, siddha and modern diagnostic methods are detail analyzed. 
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2. AIMS AND OBJECTIVES 
Objective: 
  The objective of the study is to evaluate the effect of uthamani karukku 
(Internal) in management of kana maantham. 
 
Specific Aim I: 
Collection, authentication and purification of the raw materials followed by 
preparation of the trial drug uthamani karukku. 
 
Specific Aim II: 
Preclinical screening of the trial drug Uthamani karukku for the proposed   
pharmacological activity. 
 
Specific Aim III: 
Clinical evaluation of the potency of trial drug Uthamani karukku in  the 
management of kana maantham. 
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2. REVIEW OF LITERATURE  
SIDDHA ASPECTS 
! OhX?! -tjl?! -e<hl<?! hq{q?! &h<H?! sig<giM! NXl<! gVuqz<! njlh<H!
we<X!Ne<OxiIgt<!wz<jz!hMk<kq!juk<Kt<tei</!!niqkiqK!lieqmvib<!hqxk<kz<!
niqK!we<hKl<!Ne<OxiI!uig<G!weOu!hqxh<Hgtqz<!dbi<uie!leqk!hqxuqbqe<!
Ofig<gl<!Ofibqe<xq!ofMr<gizk<K!uip<kOz/!
 
  Flk;ig jdpj;Jxopag; Gs;gwe; jw;Nw 
  clk;NghL caphpil el;G.     
- Fws; (338);;;  
 
        jhd;gpwe;j $lhdJ jdpNa fplf;f> mjDs; ,Ue;j gwit> gUtk; 
te;jTld; gwe;J Nghtijg; Nghd;wNj clk;Gf;Fk; capUf;FKs;s 
njhlh;ghFk;. 
 
  thAtpdhy; Ma clk;gpd; gaNd 
  MAtpd; vy;iy mJ. 
- xsitf; Fws;;; ; 
 
,jd; %yk; czug;gLk; fUj;J ahnjdpd; jr thAf;fshd gpuhzd;> 
mghdd;> tpahdd;> cjhdd;> rkhdd;> ehfd;> $h;kd;> fpUfud;> Njtjj;jd;> 
jdQ;nrad; Mfpatw;wpd; gaid Mjhukhff; nfhz;Nl> kdpjdpd; MAs; 
mike;Js;sJ. 
,t; thAtpd; khw;wj;jpdhy; Neha; vw;gLfpwJ mt;thW vw;gLk; Neha; 
epiyfspy; xd;Nw khe;jk;. ,k;khe;j khdJ ghythflk; vd;Dk; E}ypy; fUtpy; 
Njhd;Wk; Neha;fspd; fPo; fhzg;gLk; mff;fhuz Neha;fSs; xd;whf 
fUjg;gLfpwJ. 
 
khe;jk;:; ;; ;; ;  
NtW ngah;;;; - ke;jk; 
gps;isg; gpzp kUj;Jtj;jpy; ke;jk;> myrk;> myrfk; vd;W 
$wg;gl;Ls;sJ. 
  
khe;jk; ,ay;:; ; ;; ; ;; ; ;  
        ke;j ,ay;GilaJ khe;jk; vdg;gLk;.  
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        ke;jk; vd;gJ cUt epiyapy; clypy; ke;jk;. mUt epiyapy; 
mff; fUtpahfpa kdk;> Gj;jp> rpj;jk;> mfq;fhuj;jpYk; ke;jk; vd;Wk; 
cah;epiyapYk; ke;jk; vd;Wk; tphpj;Jf; nfhs;sTk;. 
- ghythflk;;;; 
 
cz;l czT nrhpahky; tapw;wpy; Gspj;J> tapWg;gp ,iue;J tapw;wpy; 
ke;jj;ij cz;lhf;fp> the;jpiaAk; fopr;riyAk; Vw;gLj;jp> Jd;gj;ij 
cz;lhf;Fk; Neha;. 
- gps;isg; gpzp kUj;Jtk;; ; ; ;; ; ; ;; ; ; ; 
 
  Mj;k ul;rhkph;jk; vd;Dk; itj;jpa rhu rq;fpuf; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;  E}ypy; khe;jk; jha;  
Kiyg;ghyhy; cz;lhfpwJ vd;W $wg;gl;Ls;sJ. 
 
  jd;te;jphp ghythflj; jpul;by;; ; ; ; ;; ; ; ; ;; ; ; ; ; #lhd khe;jnky;yhe; jha;g;ghy; ke;jk; 
vd;W vLj;Jiuf;fg;gl;Ls;sJ. 
 
  mgpjhd rpe;jhkzpapy;;; ; khe;jNuhfk; gps;isfSf; Fz;lhFk; 
Nuhfq;fspnyhd;W. ,J jha; Njq;fha;> nty;yk;> Rz;lw;fwp> fPiu> kPd;> 
,iwr;rp> Gspj;jNkhh;> fpoq;Ffs;> ke;jt];Jf;fs; jpd;gjhy; ghiyf; Fbf;Fk; 
gps;isfSf;Fz;lhFk; Nuhfk;. ,J gytpjkhd fopr;ry;> Ruk;> kaf;fk; 
Kjypad jUk; vd;W $wg;gl;Ls;sJ. 
 
  Fk;gKdp ghythfl E}ypy;;; ; ngUfp tUk; chpa fpUkpfNs khe;jk; 
Nrh;tjw;F fhuzk; vd;W $wpapUg;gJ Fwpg;gpljf;fJ. 
   mij fPo;f;fhZk; Nkw;Nfhshy; mwpayhk;. 
 
  'tUKhpa fpUkpfs; ngUfp tUtjpdhNy NrUNk khe;jkJ jhd;" 
 
- Fk;gKdp ghythflk; (g.vz;: 72); ; ;; ; ;; ; ;  
khe;j Neha; tUk; top:; ; ;; ; ;; ; ;  
    'khe;j Neha;top tFf;Fq; fhiy 
    tha;e;j jhahh; kftpid aPd;w 
    gpd;d uhz;bw; ngah; rU FWePh; 
    td;ik naUikg; ghy; tU GspNkhh; 
    me;nea; thio aUq;fdp khq;fdp 
    ed;ikj; Njq;fha; ey;yps ePUk; 
    fliy nty;yq; fhl;bw; Wtiu 
    mly;nkhr; irg;Gsp ak;gUg; Gg;gUg; 
    GUz;il khg;nghU SWkjp urkhpl; 
    nghUSt NrhW Nghj tUe;jy; 
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    ghfy; fs;Sz; ghpa TSit 
    VFk; this naa;tuhy; nfz;il 
    ,tw;iw Az;z nyopYz; tpd;nghO 
    jtj;ijr; Rukpit abaha;g; gyrpy 
    va;jpd; kyf;fl; Nlwp Aly;fd 
    Ka;jp apd;wp Az;lh ke;jg; 
    ghiy Az;l ghyfh;f;F 
    NkY kaph;f;$r; Rz;lha; kpFRuk; 
    rhyf; fopr;ry; rhUq; Fwprpy 
    khe;j Kz;lha; tUnkd; 
    wha;e;j kUj;Jt uwpe;Jiuj;jdNu" 
                                          - ghythflk; (g.vz;:27); ;; ;; ;  
nghUs;:;;;  
    jhahdts; Foe;ij gpwe;j Xuhz;bw;Fs; ePh;epiyfspy; gOj;J cjph;e;j 
rUFfs; tpOe;J mOfpapUf;Fk; ePiuf; Fbg;gjhYk;> vUikg;ghy;> Gspj;j 
vUikNkhh;> vUiknea;> thiog;gok;> khk;gok;> Njq;fha;> ,sePh;> fliy> 
nty;yk;> nkhr;ir> Gspaq;nfhl;il> gUg;GUz;il> khtpdhw; nra;ag;gl;l 
nghUl;fs;> mjpurk;> thAg;nghUl;fs; ,itfis mjpfkhf cz;gjhYk;> 
ghfw;fha;> fs;> Cz;> nghpacSit kPd;> this kPd;> nfz;il kPd; 
,itfis cz;gjhy; Rukbj;jy; vd;Dk; rpy gy fhuzq;fshy; jha;f;F 
kyr;rpf;fy; Vw;glf;$Lk;. mjd; fhuzkhf mtsJ cly; fdj;Jj; Jd;gg;gLk; 
NghJ Foe;ijahdJ mj;jhaplk; ghy; Fbj;jhy; kaph;f;$r;Rld; $ba fha;r;ry; 
cz;lhFk;. mj;Jld; kpff;fopr;rYk; Vw;gl;L khe;j Neha;f;Fhpa rpy 
FwpFzq;fSk; cz;lhFk;. 
 
2. fhZNkke;jk; ftspf;Fkd;dj;jhy;  
  fhZNkke;jk; fLkhkprk;kPwpy; 
  fhZNkke;jk; fye;jkhg;gz;lj;jhy; 
  fhZNkke;jk; RLNkjpghYf;Nf 
 
  Nktpamd;dj;jhy; tpsq;fpajpr;rlk; 
  ghtpNanfhd;W gopAWkd;de;jhd; 
  Mtpykpje;jg;gpy IAw;WNehahFk; 
  futpypitnay;yhk; fz;Lnfhsd;dNk 
 
  md;dk;gpwe;jJ midj;JtpijapYk; 
  kd;dpantl;il kfhrPjkpuz;bdhy; 
  gd;dpgjpejpijg guhg;gunghpNahh;fs; 
  fd;dpakaf;fj;jhh; fz;bLk;NkfNk 
- jpU%yh; fUf;fpil itj;jpak;; ; ; ;; ; ; ;; ; ; ; 
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3. Nkjpg;ghy;> nea;> fjypg;gok;> Njq;fha;> ,sePh;> fliy> nty;yk;> 
Gspj;jNkhh;> khq;fp\k;> fdpfs;> kiyj;Jtiu> cSe;J> nkhr;ir> 
Gspaq;nfhl;il> cSit> thiskPd;> nfz;il> ghfy;> Riu> Kjyhd 
thAg;gz;lq;fis Foe;ijfl;F ghy; nfhLf;Fk; khjh;fs; kpFjpah 
aDrhpj;jhy; khe;j Neha; cz;lhFk;. 
- mgpjhd rpe;jhkzp;;;  
 
4. 'kjd gy yPiy njhopNy GhpA kq;ifNa khe;j kPuhW nkhd;W 
   kUtpnaO tpjkJ gfUtJ Nfspdp mhpa jkpohfNt jhd; 
   tpjdKW fpUkpahy; kr;rnkhL ,wr;rpahy; gaWgyfhukjpdhy; 
   tps;Sk; mty; fy;Y tpidAkpit cz;gjhy; thiof;fdpGspatpijahy; 
   gjdKwNt gpyhf; nfhl;ilnahL madptpij gioa tifahy; 
   gjpa Ntfhj NrhW cz;ZtjpdhYNk gr;rhprp NrhW jd;dhy 
   mjdKwNt nrkpahkpypdp cz;gjhy; cz;lTld; J}q;Ftjpdhy; 
   mjpf kyr;rpf;fy; njfpahkNyapdp Mkhraj;jpNy jhd;"  
- Fk;gKdp ghythflk; (g. vz;:71); ; ;; ; ;; ; ;  
  vd;W khe;j Neha; tUk; top gw;wp $wg;gl;Ls;sJ.  
,jd; nghUs;:; ;; ;; ;  
fpUkpfshy; khe;jk; tUk;; ; ; ;; ; ; ;; ; ; ; 
kPd; Kjypa ,iwr;rpahYk;> mty; cz;gjhYk;> gaW Nghd;w 
gyfhuq;fshYk; thiog;g+> Gspatpij> gyhf;nfhl;il ,itfis mjpfkhf 
cz;zy; gioa czT> Ntfhj NrhW> gr;rhprp NrhW cz;gjhYk; 
cz;lTld; J}q;FtjpdhYk;> mjpf kyr;rpf;fyhYk;> Mkhraj;jpy; ke;jk; 
cz;lhfpwJ. 
 
5. Stomach upsets (maantham): 
 The reasons for child getting maantham are that the feeding mother eats all 
diet without any restrictions; she enters into sexual contact with the male and feeds 
the baby. The mother’s heat is transmitted to the baby by her milk. This milk is 
indigestible and causes maantham. 
     - Siddha system of pediatrics (ChidambaraThanupPillai) 
 
 6. 'md;dKk; ghYnea;A kiltpyhg; goKk; tpj;Jk; 
    gpd;idAk; gaW Njq;fha; nghpaNjhh; fjypf;fhAk; 
    jpd;dNt fhy;F sph;e;J jPnad ntJg;gq; fz;lhy; 
    cd;Dew; ghy fh;f;F khe;jKw; wpLnkd; whNu" 
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   'md;id Kiyg;ghYz; ljpd;Nkyh tpd;ghiy 
    cz;zpy; tapw;wp DiurPjk;- gpd;idj; 
    jpuz;L ngUe;jpiuahQ; NrapioaPh; NfsPh; 
    kUz;LisA ehSk; tapW" 
                   - guuhrNrfuk; ghyNuhfepjhdk; (g.vz;:14); ; ;; ; ;; ; ;  
 
nghUs;:;;;  
Foe;ijfs; jha;g;ghiy cz;lgpd; gRk;ghiy Nkw;nfhz;L 
Fbg;gjpdhYk; xd;Wf;nfhd;W khWgl;l epiyapy; tapw;Wj;jP ke;jg;gl;L rPjk; 
kpFe;J Fbj;j ghy; rPuzpf;fhky; the;jp vLf;Fk;. tpopkUl;rp vw;gLk;> 
fopr;rYf;F VJthFk;. 
 
7.   'Kisj;j fhuzq;fs; gw;wp fPo;f;fz;lthW $Wfpwhh; 
     tsh;e;j gps;isiar; #o;e;J kype;jpLt; 
     fpisj;j rh;f;fiu ts;spf; fpoq;Fld; 
     njspj;j khq;fdp njq;F gyhtpw;Nf" 
 
     gykjq; fl;Lg;ghy; Riu gPh;f;fq;fha; 
     myWk; thio atiu JtiuAq; 
     fpykjhf;fpLq; fPiuj;jz;bd; fwp 
     FyT khq;fliy jidf; nfhs;sNt 
 
     nfhs;sNt nrk;Gypj;jfh; NfhopkP 
     nds;sw; gd;wpf;fwp gy;ypiwr;rpA 
     Ks;Sf;fd;id epjKz;lf;fhw; 
     gps;isf;Fg; gykhe;jk; ngUFNk" 
- ruNge;jpuh; itj;jpa Kiw fh;g;gpzp ; ; ; ; ;; ; ; ; ;; ; ; ; ;
ghyNuhf rpfpr;ir (gf;fk;; ; ;; ; ;; ; ;-49) 
 
nghUs;:;;;   
     Foe;ij gpwe;j gpd; jhahh; fPo;f;fz;l czTg; gjhh;j;jq;fis 
mjpfkhfr; rhg;gpLtjpdhy; Vw;gl;l jha;g;ghiy rpR gUFtjpdhy; gw;gy 
Neha;fs; Foe;ijf;F cz;lhFk;. mit rh;f;fiu ts;spf;fpoq;F> khk;gok;> 
Njq;fha;> gyhg;gok;> ghy;> Riuf;fha;> gPh;f;fq;fha;> thiog;g+> mtiuf;fha;> 
Jtuk;gUg;G> fPiuj;jz;L> fliy> nrk;kwpahl;L khkprk;> Nfhopkhkprk;> kPd;> 
gd;wpf;fwp> cLk;Gf;fwp Kjypaitfis mbf;fb jhahh; rhg;gpLtjhy; 
Foe;ijf;F gytpj khe;j Neha;fs; cz;lhfpd;wd. 
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khe;jk; tiffs;:; ; ;; ; ;; ; ;  
   
Table 1: 
ghythflk; 
 
21 tif 
khe;jk; 
 
tsp khe;jk; 
moy; khe;jk; 
Ia khe;jk; 
tpl khe;jk; 
Nghh; khe;jk; 
thiykhe;jk; 
Ru khe;jk; 
tPf;f khe;jk; 
 
 
ePh; khe;jk; 
nrhpahkhe;jk; 
fl;L khe;jk; 
ghy; khe;jk; 
vhp khe;jk; 
Jiy khe;jk; 
jiy khe;jk; 
fz khe;jk;; ;; ;; ; 
typg;G khe;jk; 
Rop khe;jk; 
Kf;F khe;jk; 
rd;dp khe;jk; 
Cjy; khe;jk; 
tPf;f khe;jk; 
mgpjhd 
rpe;jhkzp 
 
18 tif 
 
nrhpahkhe;jk;  
gPh; khe;jk; 
Ru khe;jk; 
tpl khe;jk; 
Rop khe;jk; 
CJ khe;jk; 
ePh; khe;jk; 
jiy khe;jk; 
rpq;fp khe;jk; 
fz khe;jk;; ;; ;; ; 
nrhUF khe;jk; 
Fop khe;jk; 
,Og;G khe;jk; 
cg;G khe;jk; 
,iug;G khe;jk; 
fl;L khe;jk; 
ms;S khe;jk; 
tpf;fy; khe;jk; 
re;ep khe;jk; 
gjpnzd; 
rpj;jh;fs;  
itj;jpa 
 rpy;yiwf; 
Nfhit 
8 tif 
 
nrhpahkhe;jk; 
jiy khe;jk; 
Nghh; khe;jk; 
Rop khe;jk; 
  
 
fl;L khe;jk; 
tpr khe;jk; 
ePh; khe;jk; 
fz khe;jk;; ;; ;; ; 
 
 
jd;te;jphp 
ghythflj; 
jpul;L 
 
21 tif 
 
tsp khe;jk; 
moy; khe;jk; 
Ia khe;jk; 
tpl khe;jk; 
Nghh; khe;jk; 
thiy khe;jk; 
Ru khe;jk; 
  
ePh; khe;jk; 
nrhpahkhe;jk; 
fl;L khe;jk; 
ghy; khe;jk; 
vhp khe;jk; 
Jiy khe;jk; 
jiy khe;jk; 
 
 
fz khe;jk;;; ; 
typg;G khe;jk; 
Rop khe;jk; 
Kf;F khe;jk; 
rd;dp khe;jk; 
Cjy; khe;jk; 
tPf;f khe;jk; 
T.V. 
rhk;grptk; 
gps;is 
mfuhjp Vol 
III 
21 tif 
21 tif 
nkhj;jk;  
42 tif 
thj khe;jk;  
gpj;j khe;jk; 
rpNyl;Lk khe;jk; 
tpr khe;jk; 
Nghh; khe;jk; 
Ru khe;jk; 
ePh; khe;jk; 
nrhpah khe;jk; 
Ngjp khe;jk; 
Gsp khe;jk;  
thiy khe;jk; 
ePh;f;fz khe;jk; 
Kf;F khe;jk; 
rd;dp khe;jk; 
CJ khe;jk; 
tPf;f khe;jk; 
 
Ru khe;jk; 
ePh; khe;jk; 
nrhpah khe;jk; 
Ngjp khe;jk; 
Gsp khe;jk;  
thiy khe;jk; 
rj;jp khe;jk;  
cg;gy; khe;jk; 
ms;S khe;jk; 
fop khe;jk; 
tul;rp khe;jk; 
fh;g;g khe;jk; 
cg;G khe;jk; 
mil khe;jk; 
 
jpl;L khe;jk; 
fl;L khe;jk; 
ghy; khe;jk; 
vhp khe;jk; 
Jiy khe;jk; 
jiy khe;jk; 
fz khe;jk;; ;; ;; ; 
typg;G khe;jk; 
Rop khe;jk; 
cis khe;jk; 
Nga; khe;jk; 
rd;dp khe;jk; 
ghj khe;jk; 
,Og;G khe;jk; 
fy; khe;jk; 
Njhl khe;jk; 
the;jp khe;jk; 
mf;fu khe;jk; 
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ruNge;jpuh; 
itj;jpa 
Kiw  
fh;g;gpzp 
ghyNuhf 
rpfpr;ir 
 
17 tif 
 
jiy khe;jk; 
tpr khe;jk; 
ePh; khe;jk; 
nrhpah khe;jk; 
tws; khe;jk; 
fl;L khe;jk; 
 
 
ghy; khe;jk; 
CJ khe;jk; 
fy; khe;jk; 
typg;G khe;jk; 
Nghh; khe;jk; 
 
re;ep khe;jk; 
Nga; khe;jk; 
Jiy khe;jk; 
Ru khe;jk; 
cg;G khe;jk; 
fz khe;jk;; ;; ;; ; 
 
Mj;kul;rhkph;
jk; vd;Dk;  
itj;jpa 
rhurq;fpufk;  
 
20 tif 
 
thj khe;jk; 
gpj;j khe;jk; 
rpNyj;Jk khe;jk; 
tpl khe;jk; 
nrhpah khe;jk; 
fl;L khe;jk; 
vhp khe;jk; 
tis khe;jk; 
 
fz khe;jk;; ;; ;; ; 
typg;G khe;jk; 
Kf;F khe;jk; 
rd;dp khe;jk; 
CJ khe;jk; 
tPf;f khe;jk; 
Nghh; khe;jk; 
jiy khe;jk; 
Jiy khe;jk 
CJ khe;jk; 
tPf;f khe;jk; 
ePh; khe;jk; 
Nghh; khe;jk; 
ghy; khe;jk; 
ePh; khe;jk; 
Rop khe;jk; 
ghy; khe;jk; 
 
Siddha system 
of pediatrics 
(ChidambaraT
hanupPillai) 
 
10 types 
Ulai maantham 
Uthu maantham 
Karpa maantham 
Sura maantham 
Kana maantham 
Indigestive 
maantham 
 
Dosha 
maantham 
Vali maantham 
Pall maantham 
Eluppu 
maantham 
 
 
khe;j FwpFzk;:; ;; ;; ;   
  1.    rhh;e;jplNt ghyDly; ntJg;gpNth;f;Fk; 
                rw;WKiy Az;zhJ the;jpgz;Zk; 
      $h;e;jplNt kjpkaq;FQ; rPjk;tPOk; 
                Fzq;nfl;L kykhAk; nfl;lghy;Nghy; 
      Njh;e;jplNt njspe;jjz;zPh; Nghy;fopAk; 
                Njfk;ntg;G ehw;wKq; fhy;ifFsph;g;ghk; 
      Mh;j;jplNt ehTyUq; FuYq;fk;Kk; 
                mg;gNd fz;Fsph;e;J RoYkhNk. 
 
       Foe;ijAly; ntJk;gp tpah;f;Fk; KiyAz;zhJ the;jp gz;zp 
kaq;Fk; rPjKk; kyKkhAq; nfl;l ghy;NghYe; njspe;j jz;zPh; NghYq;fopAk; 
ntg;GehWk; iffhy; FspUk; ehTyUq; Fuy;fk;Kk; fz;Fope;J Rod;W 
rptf;Fk; fhy;gpd;Dk; Kfk; gspq;FNghy; kpd;Dk;. 
 
2. ghythfl E}ypy; ;;; $wg;gl;Ls;sit:; ; ;; ; ;; ; ;  
       Foe;ijapd; cly; fdj;jpUf;Fk;> Nehjy; cz;lhFk;. 
       kpFjpahd tpah;it cz;lhFk;. 
       RWRWg;G ,y;yhky; Nrhh;e;J ,Uf;Fk;. 
       kaf;fk; cz;lhFk;> fz; rpte;jpUf;Fk;. 
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       fz; Fop tpOe;J fhZk;. 
       Kfk; ntSj;jpUf;Fk;. 
       jhaplk; ghYz;zhJ> tha; cyUk;> Fuy; jhOk;. 
       grp Vw;glhJ> the;jp cz;lhFk;. 
       rPjKk; kyKkhfTk;> nfl;Lg;Nghd ghy; NghyTk;> jz;zPh;    
NghyTk; gy epwkhfTk; NgjpahFk;. 
       if fhy;fs; #L ,y;yhky; Fsph;e;jpUf;Fk;> Foe;ij  ifapy; 
jq;fhky; mOk;. 
 
3. ruNge;;;;jpuh; itj;jpaKiwapy; khe;jf; FwpFzq;fs; fPo;f;fz;lthW ; ; ; ; ; ; ; P ; ; ;; ; ; ; ; ; ; P ; ; ;; ; ; ; ; ; ; P ; ; ;
$wg;gl;Ls;sJ.; ; ;; ; ;; ; ;  
   'khe;jkhdJ fz;bby; tapW Tg;gprkha;r; 
   Nrh;e;j NgjpAk; gw;gy tpjq;fsha;r; nrwpe;J 
   the;jpNahL nka;kaf;fKq; FspUld; ntg;Gq; 
   fhe;JjhfTk; gpuikAq; fz;kaq;fpLNk" 
- ruNge;jpuh; ; ;; ;; ; itj;jpaKiw (g.vz;:50); ;; ;; ;  
 
nghUs;:;;;  
       Foe;ijf;F tapw;Wg;nghUky; cz;lhFk; 
       mbf;fb NgjpahFk; 
       gw;gy tpjq;fsha; the;jpAnkLf;Fk; 
       mbf;fb kaq;fpf; fplf;Fk; 
       Fsph; Ruk; fhZk;. 
 
4.  'Jbj;jplf; fhy; Fsph;e;J JZf;nfd fopr;rw;Nwhd;wp 
    mbf;fb aOJgps;is ayh;e;Jfz; NrhUkhfpw; 
    fLj;jpL khe;jnkd;W fopwpd uhAy;Ntjh; 
    gpbj;jpL tifANkw;w rpfpr;irAk; gfuYw;whk;" 
- guuhrNrfuk; (g.vz;:14); ;; ;; ;  
 fhy; Fsph;e;J fhZk; 
 fopr;ry; 
 Foe;ij mbf;fb mOjy; 
 fz; Nrhh;e;J fhzg;gLk; Mfpait khe;jj;jpd; FwpFzq;fs;. 
 
5.  
• The clinical features of the baby are that it may have dysentery, vomiting, 
fever, heaviness of the body. 
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• The baby’s stomach would be found bloated, high temperature could be felt 
on the baby, face would be pale, and tongue would become dry. 
• The baby would be yawning on and off, both of its hands and legs would be 
tired.  
• The baby would look like an owl.  
• The food would not be digested.  
• The baby would dislike milk; at times both the eye- balls would be stuck up. 
- Siddha system of pediatrics    
(ChidambaraThanupPillai) 
NtWngah;fSk; mit $wg;gl;bUf;Fk; E}y;fSk;:; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;  
fzkhe;jk;;; ;  -  ghythflk;> ruNge;jpu itj;jpa Kiw  
fh;g;gpzp  ghyNuhfrpfpr;ir 
fizkhe;jk;; ;; ;; ;  -  gps;isg;gpzp thflk; 
rpNyw;gd khe;jk;; ; ;; ; ;; ; ; -  kjiyNeha; kUj;Jtk; 
Nrh;g;g khe;jk;; ; ; ;; ; ; ;; ; ; ; -  Fk;gKdp ghythflk;  
 
Neha; ;;; tUk; taJ:;;;  
    'Mz;nlhd;iwj; njhl;Nl afy; %d;whkhz;lsTk; 
     jhz;LNk khe;j Neha; jhd;" 
- ghythflk; (ghly; vz;; ; ;; ; ;; ; ;-87)   
khe;jk; ghw;gUt Neha; vd;Wk; Foe;ijapd; Kjyhz;L Kjy; 
%d;whz;Lfs; tiu njhlUk; vd;Wk; $wpapUe;jhYk; Nkw;$wpa ghythflg; 
ghlypd;gb khe;jNeha; %d;whz;Lfisj; jhz;bAk; Foe;ijf;F ghjpg;ig 
Vw;gLj;jyhk; vd mwpfpNwhk;. vdNt xd;W Kjy; gd;dpuz;L taJf;Fl;gl;l 
fzkhe;jj;jhy; ghjpf;fg;gl;l Foe;ijfs; Ma;Tf;F vLj;Jf; nfhs;sg;gl;ldh;. 
 
fzkhe;jk; Fzk;:; ; ;; ; ;; ; ;  
,dp fzkhe;jk; FwpFzq;fs; gw;wp E}y;fspy; $wg;gl;Ls;s 
fUj;Jf;fisf; fhzyhk;. 
1.  'mUe;J nka;apisj; jpUkY kbf;fbr; RuKe; 
    jpUe;J %f;fpy; ePh; tbjYk; tapWg;Gk; rpuNeha; 
    Ghpe;jp iur;rYk; gytpjk; tapW Nghf;FlNd  
    tUe;J fz;zpdpy; kaf;fK khq;fz khe;jk;" 
        - ruNge;jpuh; itj;jpa Kiw fh;g;gpzp ghyNuhf r; ; ; ; ;; ; ; ; ;; ; ; ; ; pfpr;ir (g.vz;:56); ;; ;; ;  
                   - ghythflk; (g.vz;:111); ;; ;; ;  
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   2.   ghyd; Njfk; ,isf;Fk;> nghUky;> the;jp> tha;ePh;> jiyRw;wy;> 
Nrhgjhg mrjpfhZk;> tapW ,iue;J ghrpNghw; fopAk;> tpop RoYk;> eh 
cyUk;. 
- Mj;kul;rhkph;jnkd;Dk; itj;jpa ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;
rhurq;fpufk;; ;; ;; ; 
3. fzkhe;j;;; k;:; ;;  
    ghyd; Njfkpisf;Fk;> nghUky;> the;jp> tha;ePh;> jiy Row;wy;> Nrhgjhg 
krjpfhZk;> tapWapiwe;J ghrpNghw; fopAk;> tpopRoYk;> ehTyUk;. 
        - Nfhrhap mDNghf itj;jpa gpuk;k ufrpak; ghfk;; ; ; ;; ; ; ;; ; ; ;- 2 
  
4.  kjiy Neha;njhFjp I y; $wg;gl;Ls;s rpNyw;gd khe;jj;jpd; FwpFzq;fs; 
fzkhe;jj;jpd; FwpFzq;fis xj;Js;sd. 
 
',UkpLk; RuTk; fhAk; ,Utpyhg;Gz;Zz;lhFk; 
nrUkpLk; fgKz;lhk; Nrh;jiy fha;r;ryhfp 
epwkjha; CjpCjp ePuJ NghNy Ngjp 
kUtpNa fope;J gpd;Nd kaf;fkha; fplf;Fk; ghNu" 
- kjiy Neha;njhF;;; jp I 
  
rpNyw;gd khe;j FwpFzq;fs;:; ; ; ;; ; ; ;; ; ; ;  
 ,Uky; 
 Ruk; fha;jy; 
 ,UtpyhtpYk; Gz;Zz;lhjy; 
 fgKz;lhjy; 
 jiyfha;r;ry;- jiytyp 
 epwk; ntSj;jy; 
 ePh; Nghy Ngjpahjy; 
 kaf;fkha; fplj;jy; Mfpa FwpFzq;fis nfhz;bUf;Fk;. 
 
5.  ',Uky; %f;fhy; ePh; tbAk; ,ilA 
        kpilAk; Ruk; Njhd;Wk; 
    nghUKk; tapWk; ,iwr;ry; cz;lha; 
         Nghjf; fopAk; gytPz(d)k; 
    nrUKk; clYNk nkype;J jiy 
         Nrhh;Nt ,Uf;fnthl;lhJ 
    jUke; jdf;F(f;) fzkhe;jk; fhNz 
         ,jid Kj;jhdhpNa" 
- gps;isg;gpzp thflk;; ; ;; ; ;; ; ; 
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 ,Uky; 
 %f;fpy; ePh;tbjy; 
 ,ilapilNa Ruk; 
 tapW nghUky; ,iur;ry; 
 kpFjpahff; fopjy; 
 gytPdkiljy; 
 cly; nkypjy; 
 jiyNrhh;T 
     ,f;FwpFzq;fs; ghythfl E}ypy; $wg;gl;l fzkhe;jf; 
FwpFzq;fisg; Nghy; cs;sJ. 
 
Kf;Fw;wk; Kjypa NtWghL:; ; ;; ; ;; ; ;  
'thjnkDk; ehbaJ Njhd;wpy; 
 rPjke;jnkhL tapW nghUky; jpul;rp tha;T" 
- rjf ehb 
 
Njiuah; $w;Wgb gpzpfspd; Kjw;fhuzk;:; ; ; ; ;; ; ; ; ;; ; ; ; ;  
'ke;jkyhJ thA tuhJ" 
'Fly; jd;dpy; rPjkyhJ Ruk; tuhJ" 
'mrPuzkpd;wp Ruk; tuhJ"  
,jd;gb 
                fgf;Fw;wk; kpFjpapdhy; 
 
                   
 
                 
              tapw;wpy; Ia kpFjp Vh;gLfpwJ 
 
 
 
 
         ,jdhy; fPofz;l thA NflilfpwJ (ke;jkyhJ thA tuhJ) 
 
        Nky;Nehf;Fq;fhy; ghjpg;G- ,Uky;> %f;FePh; gha;jy;> the;jp 
        fPo;Nehf;Fq;fhy; ghjpg;G- fopr;ry; 
        rkhdthA ghjpg;G- czT nrhpahik 
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               nrhpahj czT gf;Fthrak; nry;yy; 
 
 
 
 
               md;d urk; nry;Yk; Jisfs; milgl;Lk;> 
               kaph;f;fhy;fs; (Intestinal Villi) RUq;fpAk; ,Uj;jyhy;  
              urk; cwpQ;rg;glhky; Fly; jd;dpy; rPjk; cz;lhjy; 
 
 
 
            ,jdhy; Ruk; Vw;gLfpwJ (Fly; jd;dpy; rPjkyhJ Ruk; tuhJ) 
                  mrPuzkd;wp Ruk; tuhJ (khe;jk;) 
 
 
   
 
           ehl;gl;l epiy my;yJ mbf;fb ghjpg;G Vw;gLk; NghJ 
 
 
 
             tsh;r;rp ke;jk; Vw;gLfpwJ (jpR cwpQ;ry; Fiwtjhy;) 
                      (Failure to weight gain) 
 
 
 
             Cl;lf;FiwT> cly; ,isj;jy; (Emaciation) 
 
 
 
 
               mLj;jLj;J Neha;j; njhw;W jhf;Fjy; 
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fzkhe;jjpy; Kf;Fw;wq;fspd; epiy:       ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
    rpj;j kUj;Jthq;f RUf;fj;jpy; tsp> moy;> Iak; ,tw;wpd; tiffs; 
kw;Wk; njhopy;fs; gw;wp $wg;gl;Ls;sJ.  
 
thjk;:;;;  tsp xd;whapUg;gpDk; jk; ,lk;> njhopy; Kjypatw;why; gj;J 
tifg;gLk;. 
 
Table 2: 
 
t.vz;;;; 
 
thjk;;;; ,Ug;gplk;; ;; ;; ; njhopy;;;; 
1 
gpuhzd; 
 
jkufj;jpdpd;W 
%f;F tiu 
 
kdk;> Gj;jp> cs;sk;> Ik;nghwp 
,itfisj; jd;dpiygLj;jp> 
fhwpAkpo;jy;> ,Uky;> Jk;ky;> Vg;gk; 
tply;> %r;R tply; thq;fy; cz;Zk; 
czit cl;nrYj;Jjy;> nrhpf;fr; 
nra;jy; Mfpait. 
 
2 mghdd; 
vUthapdpd;W 
mbtapU 
,Lg;gpd; g+l;L> 
ePh;g;ig> Mz;> 
ngz; Fwpfs;> 
njhil. 
 
ntz;zPh; ehjk;> kyk;> rpWePh;> fU 
,tw;iw ntspgLj;Jk;. md;d rhuj;ij 
NruNtz;ba ,lq;fspy; Nrh;g;gpf;Fk;. 
 
4 
tpahdd; 
 
jkufk; 
elj;jy;> cly; cWg;Gfis mirj;jy;> 
cz;Zk; cztpd; rhuj;ij 
mt;tplq;fspy; epiwg;gpj;J cliyf; 
fhf;Fk;. 
 
3 
cjhdd; 
 
khh;G 
 
cztpd; rhuj;ijf; $bapUe;J mij 
mq;fq;Nf epWj;jpAk; ntspgLj;jpAk;> 
fyf;fpAk; tUjy; nra;Ak;> Ngr;Rf;F 
Kjw;fhuzk;> cly; td;ik. 
 
5 
rkhdd; 
 
(gf;Fthrak;) 
tapW 
 
,J ehgpapypUe;J fhy; tiuf;Fk; 
rkdha;g; gutpg; gha;e;J kw;w 
thAf;fis kpQ;r nthl;lhky; klf;fpr; 
rhpg;gLj;jp Nrug;gz;Zk; 
mWRitfisAk;> jz;zPh;> md;dk; 
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,itfisr; rkg;gLj;jp rhuj;ijg; 
gphpj;J clypy; vy;yhg; gFjpf;Fk; 
NrUk;gb nra;Ak;. 
 
6 
ehfd; 
 
fz; 
 
fz;fis jpwf;fTk; ,ikf;fTk; 
nra;Ak;> kaph;fis rpyph;f;fr; nra;Ak;. 
 
7 
$h;kd; 
 
kdjpypUe;J 
fz;tiu 
 
,ikia nfhl;Ltpf;Fk;> nfhl;lhtp 
tplg;gz;Zk; thia %lg;gz;Zk;. 
 
8 
fpUfud; 
 
ehf;F 
 
ehtpw;frpitAk;> ehrpapw; frpitAk; 
cz;lhf;Fk;> grpia cz;lhf;Fk;> 
Jk;ky;> ,Uky; cz;lhf;Fk; xd;iw 
epidj;jpUf;fr; nra;Ak;> Nghjw; 
njhopiyr; nra;Ak;. 
 
9 
Njtjj;jd; 
 
Fjk;> Fa;ak; 
 
Nrhk;giyAk;> cly;Kwpj;jiyAk; 
cz;lhf;Fk;. jh;f;fk; Ngry;> 
rz;ilf;nfhs;sy; ,jd; njhopyhFk;. 
 
10 
jdQ;nrad; 
 
%f;F 
 
cly; KOikAk; tPq;fr;nra;Ak;> fhjpy; 
fly; Nghypiur;rypl;L> ,we;jgpd; fhw;W 
ntspg;gl;lgpd;dh; %d;whk; ehspy; 
jiyntbj;j gpd; ntspNaWk;. 
 
 
fzkhe;jjpy; ghjpg;gle;Js;s thAf;fs;:; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ;  
gpuhzd;;;; -  %r;Rtply; thq;Fjypy; ghjpg;G> ,Uky;> Jk;ky;. 
mghdd;;;; -  gytpj tapw;WNghf;F 
tpahdd;;;; -  cz;Zk; cztpd; rhuj;ij mt;tplq;fspy;  
epiwg;gpj;J cliyf; fhf;Fk; njhopy; 
ghjpg;gile;Js;sJ 
rkhdd;;;; - kw;w fhy;fis rkg;gLj;j ,ayhik kw;Wk;  
rhuj;ij clypd; gFjpfSf;F Nrh;gjpy; 
ghjpg;gile;Js;sJ. 
fpUfud;;;; -  %f;F ePh;gha;jy;> Jk;ky;> ,Uky; fhzg;gLk;. 
Njtjj;jd;; ;; ;; ; -  clw;Nrhh;Tk;> kdr;Nrhh;Tk; fhzg;gLk;. 
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gpj;jk:;; ;; ;; ; 
 
Table 3: 
  thpir 
vz;;;; 
gpj;jk;; ;; ;; ; ,Ug;gplk;; ;; ;; ; njhopy;;;; 
1 
mdw; gpj;jk; 
 
,iug;igf;Fk; 
gf;Fthraj;jpw;Fk; 
,ilapy; 
 
ePh;tbtKs;s nghUs;fis 
twsr; nra;J cz;l 
czTg;nghUis nrhpf;Fk;gbr; 
nra;Ak;. 
2 
,uQ;rf 
gpj;jk; 
,iuf;Fly; 
 
cztpypUe;J gphpe;Jz;lhd 
rhw;Wf;Fr; nre;epwj;ijj; 
jUfpwJ. 
3 
gpuhrfk; 
 
Njhy; NjhYf;F xspiaj; jUk;. 
5 
rhjfk; 
 
jkufk; 
 
,J epiwNtw;Wk; gz;GilaJ. 
,J jkufj;jpypUe;J mwpT> 
Gj;jp> gw;W ,tw;iwf; nfhz;L 
tpUg;gkhd njhopiyr; nra;J 
Kbf;Fk;. 
4 MNyhrfk; 
fz; 
 
fz;fSf;F nghUs;fis 
njwptpf;Fk; gz;GilaJ. 
 
fz khe;jj;jpy; ghjpg;gile;Js;s moy;fs;:; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;  
 
mdw; gpj;jk;; ; ;; ; ;; ; ; - cz;l czTg; nghUl;fs; nrhpg;gjpy; ghjpg;gile;Js;sJ. 
fzkhe;jj;jpy; tapw;wpiur;ry; kw;Wk; tapWg;gy; fhzg;gLk;. rPuzr;Rug;Gfs; 
Fiwtjhy; mrPuzk; kw;Wk; grpapd;ik fhzg;gLk;. 
 
,uQ;rf gpj;jk; ;; ;; ; ; - rpyhpy; mar;nre;jts FiwT fhzg;gl;lJ. rhjf gpj;jk;- 
kdk;> Gj;jp ke;jg;gLk; Foe;ijfSf;F tpUg;gkhd njhopiyr; nra;a rpukk; 
NehpLk;. 
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Table 4: 
thpir vz;;;; Iak;;;; ,Ug;gplk;; ;; ;; ; njhopy;;;; 
1 
 
mtyk;gfk; 
 
EiuaPuy; 
 
,J  EiuaPuypypUe;J nfhz;L jd; 
,aw;if td;ikahy; jphpf];jhdj;jpw;Fk; 
cztpd; rj;jhy; jkufj;jpw;Fk; 
mbg;gilahapUe;J kw;w ehd;F Iaq;fl;F 
gw;WNfhlhf cs;sJ. 
2 
fpNyjfk; 
 
,iug;ig 
 
cz;zg;gl;l czTg;nghUs; ePh; 
Kjypaitfis <ug;gLj;jp nkj;njd 
nra;Ak;. 
3 
Nghjfk; 
 
ehf;F 
ehtpdpd;W> cz;Zk; cztpd; Ritfis 
mwpar; nra;Ak; njhopy; ,ay;G. 
4 jw;gfk; 
jiy 
 
,J jiyapdpd;W fz;fSf;F Fsph;r;rpiaj; 
jUfpwJ. 
5 
re;epfk; 
 
fPy;fs; 
 
fPy;fis xd;Nwhnlhd;W nghUj;jpj;jsur; 
nra;Ak;. 
 
fz khe;jj;jpy; ghjpg;gile;Js;s Iaq;fs;:; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;  
 
fpNyjfk;  - mjpfsT rPjj;ij Vw;gLj;Jk;. 
 
jw;gfk;  - fzkhe;jj;jpy; Ia kpFjpapdhy; mjpf Fsph;r;rp Vw;gl;L  
 rpuNeha;> %f;FePh;g;gha;jy; Mfpa FwpFzq;fs; Vw;gLfpwJ. 
 
clw;jhJf;fs;:; ; ;; ; ;; ; ;  
 
gpzpfSf;F fhuzk; Kf;Fw;wq;fs; vd;W $wpdhYk; VO 
clw;jhJf;fspd; Ntw;Wikiaf; fhuzkha;f;nfhz;L fpisf;fpd;wd vd;gjhy; 
clw;jhJf;fspd; ,aw;ifg; gz;G kw;Wk; epyk;> nghOJ ,itfspd; jd;ik 
gw;wpAk; mwptJ mtrpak;. 
  
20 
 
 
Table 5 
thpir 
vz;;;; 
clw;jhJf;fs;; ; ;; ; ;; ; ; 
 
,ay;;;; ghjpg;G;;;  
1 
rhuk;;;; 
 
cliyAk; kdijAk; Cf;fKwr; 
nra;tJ. 
 
fzkhe;jj;jpy; Ia 
kpFjpapdhy; Njhd;Wk; 
gz;Gfshfpa 
grpj;jPFiwjy;> Cf;fk; 
Fiwjy;> cly; 
ntz;zpwj;ijAk; 
Fsph;r;rpiaAk; miljy;> 
clw;fl;Lfs; jsuy;> 
cg;gprk;> ,Uky; Mfpad 
Vw;glyhk;. 
2 nre;ePh;; P ;; P ;; P ; 
mwpT td;ik> xsp> nrUf;F> xyp 
,itfis epiyf;fr; nra;tJ. 
rpy Foe;ijfspy; 
clypy; epwq;Fiwjy;> 
twl;rp> Gspg;G> 
Fsph;r;rpAs;s 
nghUs;fspy; tpUg;G 
Nghd;w nre;ePh; Fiw 
Fzk; fhzg;glyhk;. 
3 Cz;;;; 
clypd; cUtj;ij mjd; 
njhopw;fpzq;f mikj;jYk; vd;ig 
tsh;j;jYk;  nra;tJ. 
Ik;nghwpfl;Fr; Nrhh;T 
vDk; Cd; FiwFzk; 
fhzg;glyhk;. 
4 nfhOg;G;;;  
cWg;Gfs; jk; nraiy nra;Ak; 
NghJ fbdkpd;wp ,aq;f 
mtw;Wf;F nea;g;Gg;gir Cl;LtJ. 
fzkhe;jj;jpy; 
clypisj;jy; 
fhzg;gLk;. 
5 vd;G;;;  
cliy xOq;Fgl epWj;jpitj;jy;> 
nkd;ikahd cWg;Gfisg; 
ghJfhj;jy;> cly; mirtpw;F 
mbg;gilahapUj;jy;. 
vd;G Fiw Fzq;fshfpa 
efq;fs;> kaph;fs; 
ntbj;jYk;> cjph;jYk; 
fhzg;glyhk;. 
6 %is 
vd;Gf;Fs; epiwe;J mitfSf;F 
td;ikAk; nkd;ikAk; jUtJ> 
%is FiwFzk; fhzg;glyhk;. 
 
7 
Rf;fpyk;; ;; ;; ;/ 
RNuhzpjk;;;; 
fUTw;gj;jpf;F Kjyha; ,Ug;gJ. 
fzkhe;jj;jpy; Neha;j;njhw;W 
Vw;gLtijg; nghUj;Jk;> mbf;fb 
ghjpg;G Vw;gl;lhYk; ngUk;ghYk; 
midj;J cly;jhJf;fSk; 
ghjpg;gilfpd;wd. 
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  ,t;thwhf Neha;f;fpUkpfshy; cz;lhFk; Neha;j;njhw;Wfshy; VO 
cly;jhJf;fSk; ghjpg;gilfpd;wd. 
 
khe;jk; kpFe;j Fzk;:; ; ; ;; ; ; ;; ; ; ;  
    “tha;nte;J Rukjhfp te;jpLk; kpUkYz;lha; 
    Neha; te;J Ropathq;fp Etwiy typf;F kPw;wpw; 
    Ngha;te;J fLg;Gfhzpw; nghWj;Jg; gpzpuj;jq;fhZk; 
    Nta; te;j NjhspdhNy kpFe;jpLq; Fzq;flhNk 
    rpwpatd; tapW NghFQ; rpde;jpL kQ;rpg; ghh;f;Fk; 
    fwpAl Zz;l jhahh; ifapY kOjDq;Fk; 
    mwptope; Jlk;G fhA kiuf;Ff; fPo; Fsph;e;jpUf;Fk; 
    ntwp tpuw; fhy;if tPq;F kpF khe;jnkd;W NjNu" 
- guuhr Nrfuk; (gf;.15); ;; ;; ;  
jPUk; jPuh epiy:P ; PP ; PP ; P  
  khe;j Nehapy; RuKk;> Ruj;jpy; tpl Njhlk;> tPf;fk;> tapW nghUky;> 
fgk; ,it mjpfgLkhapd; jPUtJ fbdk;. 
 
jpizfs;: (epyq;fs;); ; ;; ; ;; ; ;  
jpiz vd;gJ epykhFk;. ,J 5 tifg;gLk;. 
epyq;fis gw;wp njwpe;J nfhs;tjd; %yk; cztpw;Fk; kUe;Jfs; 
nra;tjw;Fk; fpilf;Fk; nghUl;fis gw;wp mwpe;J nfhs;syhk;. NkYk; 
,d;dpd;d epyq;fspy; trpf;f cz;lhFk; Neha;fs; my;yJ ePq;Fk; Neha;fis 
gw;wp mwpayhk;. kUe;Jfs; rhg;gpl rpwe;j epyk; vJ vd;gJ gw;wpAk; clYf;F 
ed;ik> jPik juf;$ba epyj;J ePh; gw;wpAk; njwpe;J nfhs;syhk;. 
,e;epyq;fspy; trpf;f rpy Neha;fs; cz;lhFk; my;yJ ePq;Fk;. 
 
Table 6: 
FwpQ;rp;;;  
(kiy> kiyrhh;e;j epyk;); ; ;; ; ;; ; ;  
rpNyj;Jk Neha; cz;lhFk;. tapw;Ws; 
,uj;jj;ij cwpQ;Rk; RuKz;lhFk;. 
Ky;iy;;;  
(fhL> fhL rhh;e;j epyk;); ; ;; ; ;; ; ;  
gpj;jNeha; cz;lhFk; ty;iyNeha; 
cz;lhFk;. thjNeha;> thjrhh;ghd 
Neha;fSk; cz;lhFk;. 
kUjk;;;; 
(tay;> tay; rhh;e;j epyk;); ; ; ; ;; ; ; ; ;; ; ; ; ;  
ePh;tsj;jhy; thjgpj;j fg Neha;fis 
xopf;Fk;. Kj;Njhl Neha;fSk; 
cz;lhfhJ. 
nea;jy; 
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nea;jy;; ;; ;; ; 
(fly;> fly; rhh;e;j epyk;); ; ; ; ;; ; ; ; ;; ; ; ; ;  
thj Neha; cz;lhFk;. <uy; ngUf;fk; 
cz;lhFk;. 
ghiy 
(kzy;> kzy; rhh;e;j epyk;); ; ; ; ;; ; ; ; ;; ; ; ; ;  
thj gpj;j fgj;jhy; cz;lhd 
gpzpf;F ,Ug;gplk; Kj;Njhl 
Neha;fSk; cz;lhFk;. 
 
 
gUtfhyq;fs;:; ;; ;; ;  
   12 khjq;fs; nfhz;l xU Mz;il ,U gphpTfshfg; gphpj;J ,uz;buz;L 
khjq;fisf; nfhz;l xt;nthU gphpTk; fhyk; my;yJ gUtk; vdg;gLk;. 
   ,jd; %yk; xt;nthU gUt fhyj;jpYk; clypy; cz;lhFk; Neha;fisf; 
fzpf;fyhk;. 
 
• fhh;fhyk;           -  Mtzp> Gul;lhrp 
• $jph;fhyk;            -  Ig;grp> fhh;j;jpif 
• Kd;gdpf;fhyk;         -  khh;fop> ij 
• gpd;gdpf;fhyk;         -  khrp> gq;Fdp 
• ,sNtdpy;fhyk;       -  rpj;jpiu> itfhrp 
• KJNtdpy;fhyk;       -  Mdp> Mb 
 
tsp Kjypa Fw;wq;fs; jd;dpiy tsh;r;rp> Ntw;Wepiy ; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ; tsh;r;rp kw;Wk; ; ; ; ;; ; ; ;; ; ; ;
jd;dpiy milAk; fhyk;.; ; ;; ; ;; ; ;  
Table 7: 
Kf;Fw;wk;; ; ;; ; ;; ; ; jd;dpiy tsh;r;rp; ; ;; ; ;; ; ;  
Ntw;Wepiy ;;;
tsh;r;rp; ;; ;; ;  
jd;dpiy miljy;; ;; ;; ; 
thjk; KJNtdpw;fhyk; fhh;fhyk; $jph;fhyk; 
gpj;jk; fhh;fhyk; $jph;fhyk; Kd;gdpf;fhyk; 
fgk; gpd;gdpf;fhyk; ,sNtdpw;fhyk; KJNtdpw;fhyk 
 
Neha;j; jLg;G Kiw:; ; ;; ; ;; ; ;  
• ghJf;fhf;fg;gl;l FbePh; trjpAk;> Rj;jkhd czT jahhpj;jYk; rpwe;j 
jLg;G KiwfshFk;. 
• Nehapy;yh newpapy; nrhy;yg;gl;l ehs; xOf;fk;> fhy xOf;fk; ,tw;iw 
jhAk; Foe;ijAk; gpd;gw;WkhW $w Ntz;Lk;. 
• fha;fwpfs;> goq;fis ed;whff; fOtp cgNahfpf;f Ntz;Lk;. 
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• czT cz;gjw;F Kd;Dk;> kyk; fopj;j gpd;Gk; iffis ed;whf 
rTf;fhuk; Nghl;L fOt Ntz;Lk; my;yJ gbfhu ePh; nfhz;L iffis 
Rj;jg;gLj;jpf; nfhs;s mwpTWj;jg;gl;lJ. 
 
KbTiu: 
 'fz khe;jk;" vDk; Neha; khe;jj;jpd; tiffspy; kpf 
Kf;fpakhdjhFk;. Foe;ijfSf;F cz;l czthdJ tplkpj;J er;Rf; 
FwpFzq;fis Njhw;Wtpg;gNjhL. tsh;r;rpiaAk; ghjpg;gila nra;tjhf 
mike;JtpLk;. ,jdhy; Foe;ijfspd; Cl;lr;rj;Jk;> cly;eyKk; Fd;wp> gpw 
Neha;fSf;F Ml;gl;L Foe;ijapd; KbT tiuf;Fk; ,e;Neha; cl;gLj;jp 
tplyhk; vDk; Iak; Njhd;w> ,jd; tpguq;fis Ma;T nra;J jfty;fs; 
Ma;thsuhy; ,q;Nf jug;gl;Ls;sJ. 
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MODERN ASPECT 
ACUTE GASTRO ENTERITIS (AGE): 
 Kana maantham can be compared with the leading pediatric disease Acute 
Gastro Enteritis which have a higher rate of hospital admission in developing 
countries as compared to developed countries. 
  Gastroenteritis is defined as the inflammation of the mucous membranes of the 
gastrointestinal tract and is characterized by diarrhea. (Chung M Chow et al, 2010).     
It is a common childhood disease. Acute gastroenteritis causes 1.5 million visits to 
primary care providers each year and 220,000 hospital admissions for children under 
the age of 5 years. (Chung M Chow et al, 2010) 
 All children are expected to experience AGE in the first 3 years of life. 
(Guarino, Alfredo et al, 2008) 
 
Epidemiology 
 Children under 5 years of age are the most affected population, and the 
diarrheal episodes happen more frequently in Asia and Africa (Gilberto Rivera-
Dominguez et al, 2019) 
 
Etiology 
 Gastroenteritis occurs when there is a fecal-oral contact, ingestion of 
contaminated water or food and person to person, been this the most common way of 
acquiring this infection. This disease is associated with poor environmental hygiene 
and poverty. (Gilberto Rivera-Dominguez et al, 2019) 
 
Bacterial and viral causes are 
• Shigella, 
• Enterohemorrhagic Escherichia coli, 
• Campylobacter jejuni, 
• Norovirus, 
• Rotavirus, 
• Giardia lamblia, 
• Cryptosporidium parvum. 
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Food sources are 
• Leafy vegetables 
• Non- veg 
• Nuts 
• Milk protein 
 Dry conditions would tend to encourage the formation of virus-laden dust 
from fecally contaminated diapers, bedding, and clothing. 
 The exact etiologic fractions of diarrhea among children in developing 
countries are a subject of much research and our knowledge of the various pathogens 
that cause moderate to severe childhood diarrhea has grown considerably. 
 
Pathophysiology: 
 The pathophysiology depends on the organism causing the disease. It can 
cause by toxins like Staphylococcus aureus, while others increase secretion leading to 
dehydration, for example, Salmonella. Cytotoxins like Shigella and Clostridium 
difficile can invade the more susceptible tissue and cause inflammatory diarrhea. 
Enterotoxin production agents cause noninflammatory diarrhea, the virus frequently 
destroys the villus surface, and parasites adhere to the mucosa. 
 In the case of inflammatory diarrhea, there are fluid, proteins, and leukocytes 
entering the interstitial lumen. Viruses like adenovirus can directly invade the 
microvillus or through calcium-dependent endocytosis, causing the loss in the ability 
to absorb. 
 On a molecular level, agents affect the interstitial lumen by activating 
enterocyte intracellular signal transduction, affecting the cytoskeleton of the host 
cells. This will alter the water and electrolyte fluxes across the enterocytes. For toxic 
diarrhea, there is an increase of cAMP and inhibition of NaCl abortion. When 
infiltration occurs, there is histologic damage that will reduce glucose, stimulated Na, 
and electro neutral NaCl absorption. (Gilberto Rivera-Dominguez et al, 2019) 
 
Clinical features: 
• Diarrhea 
• Vomiting 
• Abdominal pain 
• Fever 
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• Headache 
• Flu like illness 
• Periumblical pain 
 Mild respiratory disease symptoms in patients with rotavirus gastroenteritis 
are usually seen. (Carl D. Brandt et al, 1982) 
 Although nausea and vomiting are non specific symptoms, they indicate 
infection in the upper intestine.  
 Fever suggests an inflammatory process but also occurs as a result of 
dehydration or coinfection (e.g., urinary tract infection, otitis media). Fever is 
common in patients with inflammatory diarrhea. 
 
Risk factors: 
 The main risk factors for gastroenteritis are environmental, seasonal, and 
demographics. Some  diseases like measles and immunodeficiency put the patient at a 
higher risk for a gastrointestinal (GI) infection. Malnutrition is another significant risk 
factor. (Gilberto Rivera-Dominguez et al, 2019) 
 Lack of exclusive or predominat breastfeeding. 
 Micronutrient malnutrition in children with Vitamin A deficiency and 
accounts for 157,000 deaths from diarrhea, measles and malaria. 
 Zinc deficiency is estimated to cause 116,000 deaths from diarrhea and 
pneumonia. (Nelson Textbook of Pediatrics, 2016) 
 Majority of cases of diarrhea resolve within the 1st week of the illness. A 
smaller proportion of diarrheal illnesses fail to resolve and persist for longer than 2 
week. 
 Persistent diarrhea is defined as episodes that began acutely but last for 14 or 
more days. 
 
Stool examination:  
 Microscopic examination of the stool and cultures can yield important 
information on the etiology of diarrhea. Stool specimens could be examined for 
mucus, blood and leukocytes. 
 In most children with uncomplicated watery diarrhea, no laboratory evaluation 
is needed except for epidemiologic purposes. 
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 The Bristol Stool Chart (BSC) allows patients to identify their stool form 
using seven different images with accompanying written descriptors. Diet of Indian 
population is quite different from many other regions of the world. Vegetarianism, 
which is associated with higher fiber intake, is common in India (Manas Kumar 
Panigrahi, 2013) Differences in gut transit time, dietary variation including fiber 
intake and consumption of non-vegetarian foods such as meat has been suggested to 
explain variation in stool frequency among different areas of the world is several 
earlier studies.  Cultural factors also influence bowel habit. Quite early in their life, 
children in some parts in India, including the region where the current study was 
undertaken are exposed to the adage "He who defecates twice a day; remains 
healthy - keeps the doctor away." 
 
 
Figure 1 
(Y. Vandenplas et al, 2011) 
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Treatment: 
 
Figure 2 
Murphy MS, 1998) 
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Management of hydration in gastroenteritis. 
 
 
Figure 3 
  
Management of feeding in gastroenteritis. (Murphy MS, 1998) 
  The essential pillars of good treatment of acute gastroenteritis always include 
the followings: 
i. Use of oral rehydration for dehydration; 
ii. Hypotonic oral rehydration solution; 
iii. Fast oral rehydration over 3 to 4 hours; 
iv. Rapid realimentation with normal feeding; 
v. Use of special formula is unjustified; 
vi. Use of diluted formula is unjustified; 
vii. Continuation of breast feeding at all time; 
viii. Supplement with oral rehydration solution for ongoing losses. 
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ix. Carbonated drinks or commercial juices with a high concentration of simple 
carbohydrates should be avoided; 
x. Lactose containing formulas are usually well tolerated, if lactose 
malabsorption appears clinically substantial, lactose- free formulas can be 
used; 
xi. Complex carbohydrates, fresh fruits, lean meats, yogurt and vegetables are all 
recommended.  
Dehydration is the main clinical feature of acute gastroenteritis and generally 
reflects disease severity. Weight loss, prolonged capillary refill time, skin turgor, and 
abnormal respiratory pattern are the best individual clinical signs of dehydration. 
(Guarino, Alfredo et al, 2008) Microbiological investigations are generally not needed 
Symptoms associated with dehydration: 
Table 8: 
 
SYMPTOMS 
MINIMAL     
DEHYDRATION 
( <3% LOSS OF BODY 
WEIGHT) 
MILD TO MODERATE 
DEHYDRATION 
(3-9% LOSS OF BODY 
WEIGHT) 
SEVERE 
DEHYDRATION 
(>9% LOSS OF BODY 
WEIGHT 
Mental status Well, alert 
Normal, fatigued, or 
restless, irritable. 
Apathetic, lethargic, 
Unconscious 
Thirst 
Drinks normally, 
might  refuse liquids 
Thirsty, 
eager to drink 
Drinks poorly, 
unable to drink 
Heart rate Normal Normal to increased 
Tachycardia, with 
bradycardia 
in most severe cases 
Quality of 
pulses 
Normal Normal to decreased 
Weak, thread, 
impalpable 
Breathing Normal Normal, fast Deep 
Eyes Normal Slightly sunken Deeply sunken 
Tears Present Decreased Absent 
Mouth and 
tongue 
Moist Dry Parched 
Skin fold Instant recoil Recoil in < 2 sec Recoil in > 2 sec 
Capillary refill Normal Prolonged Prolonged, minimal 
Extremities Warm Cool Cold, mottled, cyanotic 
Urine output 
Normal to 
decreased 
Decreased Minimal 
Nelson Textbook of Pediatrics, vol 2, pg- 1870 
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Summary of treatment based on degree of Dehydration: 
Table 9: 
Degree of 
dehydration  
Rehydration 
therapy 
Replacement of losses Nutrition  
Minimal or 
no 
dehydration  
Not applicable  
<10 kg body weight:  60 
-120 ml ORS for each 
diarrheal stool or 
vomiting episode > 10 
kg body weight 120 – 
240 ml ORS for each 
diarrheal stool or 
vomiting episode 
Continue breast feeding  or 
resume age – appropriate 
normal diet, after initial 
hydration, including adequate 
caloric intake for 
maintenance 
Mild to 
moderate 
dehydration 
ORS, 50 – 100 ml 
/ kg body weight 
over 3-4 hrs 
Same Same 
Severe 
dehydration 
Lactated ringer 
solution or normal 
saline in 20 ml/kg 
body weight IV 
until perfusion and 
mental status 
improve: then 
administer 100 
ml/kg body weight  
ORS over 4 hr or 
5% dextrose 
normal saline IV 
at twice 
maintenance fluid 
rates 
Same; if unable to drink, 
administer  through 
nasogastric tube or 
administer 5% dextrose 
in normal saline with 20 
mEq/L potassium 
chloride IV 
Same  
Nelson Textbook of Pediatrics, vol 2, pg- 1871 
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4. MATERIALS AND METHODS 
SELECTION OF PATIENTS:-  
 Primary screening was done at outpatient department(OPD)  at room no. 7 
Kuzhanthai Maruthuvam Department at Government Siddha Medical 
College(GSMC), Palayamkottai, and Tirunelveli. 20 patients of both male and female 
children were selected for the studies and admitted in postgraduate Kuzhanthai 
Maruthuvam In patients ward for at least 7days and advised for further follow up as 
our patients. Another 20 patients are treated with trial drug in the out-patients ward. . 
All cases were carefully and thoroughly examined before admission. Those who 
fulfilled the criteria of kana maantham according to the clinical features were selected 
with the aid of questionnaire. The opinion of professor and lecturer was obtained and 
detailed History was recorded in the proforma of the case sheet. 
INCLUSION CRITERIA 
 Age   :01 to 12Years 
 Sex    :  Both sex  
 Diarrhea 
 Bloating abdomen 
 Fever 
 Watery Nasal discharge 
 Cough 
 Headache 
 Drowsiness 
 Weight loss 
 The patients who have at least 3 symptoms have been selected  for the trial. 
 
EXCLUSION CRITERIA 
 Age   : Below 01 year  and above 12 Years 
 PEM (Protein Energy Malnutrition) 
 Mesenteric Adenitis 
 Peritonitis 
 Severe Dehydration  
 Pneumonia 
 Tuberculosis 
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 Criteria for withdrawal: 
 Intolerance to the drug. 
 Patient turned unwilling to continue the course of the clinical trial. 
 In case of systemic Illness 
 The investigator  remarked the probable cause of withdrawal and provided the 
probable cause of withdrawal and provided the possible medical treatment or 
referred the patients to the suitable place for further management of the illness, 
if serious condition arised. 
 In the circumference of discontinuation of the study, related all data were 
erased and the withdrawn patients replaced by new patients according to the 
inclusive and exclusive criteria. 
 
Study design: 
        At the baseline visit, the patients were screened according to the case report 
form I and selected according to inclusion and exclusion criteria after getting the 
subjects consent. There after detail history was taken from the selected subjects. 
Physical and systemic examination was done and the details recorded using case 
report form II. In addition if necessary and the patient are willing laboratory 
investigations were done and the data recorded in the case report III. 
 The subjects were investigated according to the siddha and modern diagnostic 
methods in their first visit 
 
Diagnosis method: 
 Siddha methodological assessment 
 Laboratory investigations 
 
Siddha methodological assessment 
Uyir thathukkal: 
Vatham:    
 Pranan 
 Abhanan 
 Vyanan 
 Uthanan 
 Samanan 
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 Naagan 
 Koorman 
 Kirugaran 
 Devathathan 
 Dhanajeyan 
Pitham:  
 Analam 
 Ranjagam 
 Saathagam 
 Alosagam 
 Prasagam 
Kabam:  
 Avalambagam 
 Kilethagam 
 Pothagam 
 Tharpagam 
 Santhigam 
Udalthathukal:      
 Saaram 
 Senner 
 Oon 
 Kolupu 
 Enbu 
 Moolai 
 Sukilam/ Suronitham 
EnvagaiThervugal:  
 Naadi 
 Na 
 Niram                       
 Sparism                    
 Mozhi 
 Vizhi 
 Malam    
 Moothiram           
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Modern diagnostic methods 
Stool Examination:  
 Color  of  stool:   
 Specify- 
 Consistency: 
 Specify- 
 (Bristol stool chart) 
 Presence of mucous:   
 Presence of blood:  
 Urine Examination: 
 Color  
 Urine output  
Laboratory investigation  
Blood    
Hb   
Total count   
Differential count     
        Neutrophils                
        Lymphocytes      
Monocytes          
Eosinophils        
 ESR        
Serum electrolytes    
Urine Investigation:  
Alb  
Sug  
Dep 
Stool Examination:  
Ova  
Cyst 
Occult blood  
Culture 
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5. DRUG REVIEW OF TRIAL MEDICINE 
Uthamani karukku: (Internal medicine)  
Karukku- to grind, to burn, scorch, tan, darkens by heat (Tamil Lexicon, 1982) 
                Toast (Sambasivam pillai, T.V, 1998) 
 Ingredients: 
1. Vasambu            Acorus calamus L.                                10 gram 
2. Uthamani          Pergularia daemia (Forssk.)Chiov.      100 ml 
3. uppu                  Sodium chloride                                    1 gram 
Purification of vasambu: 
The most important part of the drug preparation which makes the toxic drug 
into non toxic, it is one of the real identity of siddha system. 
usl<H!sil<hz<!G{l<< < < << < < << < < <!
! “OkXOl!usl<hiekqz<!sil<hz<kie<!
! fQXOl!szl<kie<!nkqzqm<M!d{<{qz<!
! uQXogi{<M!outquVl<!OhkqBl<!
! liXole<X!uGk<kei<!ff<kqOb!
.!sqkl<hv!kiEh<hqt<jt!ohiVm<h{<H!F~z<!higl<!.!2!
Method of preparation: 
                Vasambu  has been calcinated by traditional cow dung method, Uthamani 
leaves are collected and juice is extracted, which is mixed with salt (Sodium chloride)  
and calcinated vasambu and the mixture is heated until the juice is fully absorbed and 
made powdery, at last again it is  triturated  and (K.S.Murugesa Mudhaliar, 2013) 
given for administration. 
Dose  :  65 mg 
Adjuvant :  Hot water 
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Figure 4 
 Uthamani karukku preparation. 
              
Figure 5                   
Uthamani karukku 
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PROPERTIES OF THE DRUG Uthamani karukku: 
Uthamani: 
  A slender, hispid, fetid- smelling perennial climber. Leaves opposite, 
membranous, 3-9 cm long and wide, broadly ovate, orbicular or deeply cordate. 
 
Figure 6 
Pergularia daemia 
    Taxonomy   
           Kingdom                         :  Plantae  
Subkingdom                    :  Tracheobionta  
Super division                 :  Spermatophyta  
Division                          :  Magnoliophyta  
Class                               :  Magnoliopsida  
Subclass                          :  Asteridae  
Order                              :  Gentianales 
 Family                           :  Asclepiadaceae 
 Genus                             :  Pergularia  
Species                            :  P. daemia (Forsk) Chiov. 
Other names                    :  Veliparuthi, Uththamamaagaani,  
Uththamagannigai 
          Parts used                        :  Leaves, roots and root bark 
    Parts used in the Trial drug   :  Leaves 
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 Cuvai                               :  Kaippu 
 Tanmai                            :  Veppam 
 Pirivu                               :  Karppu 
Action :        
• Anti pyretic 
• Antispasmodic 
•  Nervine tonic 
•  Sedative 
•  Stomachic 
•  Anthelmintic 
•  Laxative 
• Expectorant (N. Balakrishnan et al 2009)  
•  Emetic 
• Anti inflammatory 
Active constituents     : 
• Lupeol 
• Beta sitosterol 
• Quercetin 
• Kaemferol 
• Alpha -Amyrin 
• Beta- Amyrin 
• Betaine 
• Isohamnetin 
 
dk<kil{q!ohiKG{l<< << << <!
! “-sqg<Gl<!uzqbqjvh<Hl<!wk<kch<Hl<!WGl<!
! hsqg<Glkq!lif<kLl<!Ohil<!hiI”!
- ngk<kqbi<!G{uigml<!
The verse denotes uthamani helps to relieve from icivu (vali), iraippu and athi 
maantham. Appetite will be increased. 
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Medicinal properties:  
Gastro Intestinal system:        
• Digestive disturbance 
• Flatulence 
• Loss of appetite 
• Gastric ulcer 
• Choleric diarrhea in children 
• Treat infantile diarrhea and 
• Malarial intermittent fevers.  
Respiratory system:       
• Cough 
• Fever 
• Cold 
• Asthma 
• Whooping cough and 
• Capillary bronchitis. 
                                                      -Nadkarni’s Indian material medica vol-I 
Acute toxicity of P. daemia  
Table 10: 
Treatment 
Dose oral  
(g/kg BW)a 
Quantal  
symptoms 
Quantal  
mortality 
Control (vehicle)         10 mg/kg                                         0/10                           0/10                                    
Test extract                       0.5                                               0/10                                    0/10                                    
 1.0                                       0/10                                    0/10                                    
 1.5                                                0/10                                    0/10                                    
 2.0                                                0/10                                    0/10                                    
 2.5                                                3/10                                    2/10                       
 3.0                                                2/0 0/10 
A g/kg body weight/os.            (S. C. Jain et al, 1998) 
 From Table 1, it is evident that the plant extract was well tolerated orally in 
mice up to a dose of 2.0 g/kg BW with no mortality or serious side effects(Jain, S. C, 
1998). 
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 Among the aqueous and ethanolic extracts tested, the ethanolic extract of the 
aerial parts of Pergularia daemia possess Hepatoprotective activity against CCl4 
intoxication in rats. ( Sureshkumar, S. V et al, 2006) 
 
Antibacterial activity of methanol, chloroform and aqueous extract of Pergularia 
daemia (Forsk.) Chiov.   
Table 11: 
S. 
N
o 
 
       Test bacteria 
                           Zone of inhibition (Diameter in mm)  
      Methanol 
extract    Chloroform extract     Aqueous extract 
  
75 
µL 
100 
µL 
125 
µL 
75  
µL 
100 
µL 
125 
µL 
75 
µL 
100 
µL 
125 
µL 
1 Escherichia coli    -    - - - - - - - 15 
2 Klebsiella pneumonia - - - 17 18 19 11 13 15 
3 Staphylococcus aureus 19 20 21 12 13 15 19 20 22 
(Ramanathan R et al, 2013) 
 The methanolic extract produced zone of inhibition against S. aureus only which 
showed 19 mm in 75µL, 20 mm in 100µL and 21 mm in 125µL concentration. In chloroform 
extract active against K. pneumoniae and S. aureus which produced 17 and 12 mm in 75µL, 
18 and 13 mm in 100µL and 19 and 15 mm in 125µL concentrations (Ramanathan R et al, 
2013). In aqueous extract was the most effective against all three test pathogens, but the 
maximum zone of inhibition was shown at 125µL concentration which produced 15mm 
against E. coli and K. pneumoniae, 22 mm zone of inhibition against S. aureus. 
 
Antifungal activity of methanol, chloroform and aqueous extract of Pergularia 
daemia (Forsk.) Chiov.  
Table 12: 
     S. 
No. Test fungi 
Zone of inhibition (Diameter in mm) 
Methanol extract Chloroform 
extract Aqueous extract 
75 
µL 
100µ
L 
125
µL 
75 
µL 
100
µL 
125
µL 
75 
µL 
100
µL 
125
µL 
1 Aspergillus niger 14 15 16 19 20 22 15 16 17 
2 Penicillium sp. 13 15 16 17 18 19 18 19 20 
(Ramanathan R et al, 2013) 
  A. niger and Penicillium sp. were highly susceptible to chloroform extract (22 and 19 
mm) followed by aqueous extract (17 and 20 mm) and methanolic extract (16 and 16mm) at 
125µL concentration respectively (Ramanathan R et al, 2013). 
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Acute toxicity study: 
 (Sureshkumar, S. V et al, 2006)The ethanolic and aqueous extracts did not 
cause any mortality up to 2000 mg/kg and were considered as safe as per OECD 
guidelines (OECD, 1996). 
Vasambu: 
 
Figure 7- Acorus calamus 
  A. calamus is a perennial plant with creeping and extensively branched, 
aromatic rhizome, cylindrical, up to2.5 cm thick, purplish-brown to light brown 
externally and white internally. At the rhizome forming, perennial that can grow to 2 
meters resembling an iris (Ushakanthan et al, 2017). 
 TAXONOMY  
Kingdom       :  Plantae 
Division             :  Magnoliophyta 
Class                   :  Liliopsida 
Order                      :  Acorales  
Family                     :  Acoraceae  
Genus                  :  Acorus  
Species                   :  calamus/ A. aromatics / A. calamus var.  
americanus  
Other species        :  Acorus gramineus 
usl<H!OuXohbi<gt<< < << < << < <!
! dg<gqvl<?!usl<?!ujs?!Ou{q?!SMuie<?!djvh<hie<?!OhI!osiz<zi!lVf<K?!
hqt<jt!lVf<K?!ogic!ogUiq?!ur<gqvisl<?!gql{k<kqh<hq?!uq]vl<?!Ylsl<?!
kqiqhr<Gsikq?!NSOukbl<?!uSf<kgqVlqbiq/!
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Parts used                               : Dried Rhizome 
Parts used in the trial drug     : Ash of the Rhizome. 
Cuvai                                     : karppu, kaippu 
tanmai                                   :  Veppam 
Pirivu                                    : karppu 
Action : 
• Stomachic 
•  Anti periodic 
• Stimulant 
•  Disinfectant 
•  Germicide 
• Carminative 
•  Expectorant and  
• Antispasmodic. 
Constituents   :   
• Alpha – asarone- 1.17% 
•  Beta- Asarone- 92.68% 
• Delta- Asarone- 2.27% 
• 1-8 cineole, Terpionolene, sugar 8.342% 
• Nitrogen 2.029%, Protein 10.318% 
•  A volatile essential oil- acronic. 
•  A bitter principle- acoretin( choline calamine) 
•  The essential oil of Acorus calamus is yellowish brown and is found to be 
composed of as aryl aldehyde, esters of palmitic acids and a small quantity of 
phenol, eugenol, methyl eugenol, calameneol and calameone. 
                                                                                 -Indian Materia Medica (P. No: 35) 
Active constituents: 
 The rhizomes of Acorus calamus Linn. has mixed fatty acids, as indicated by 
gas chromatography of the corresponding methyl esters were myristic (1.3%), 
palmitic (18.2%), palmitoleic (16.4%), stearic (7.3%), oleic (29.1%), linoleic (24.5%) 
and arachidic (3.2%). The nature of the sugars was defined by paper chromatography 
and confirmed by direct comparison with authentic samples. Composition of the 
sugars, as indicated by densitometer, was maltose (0.2%), glucose (20.7%) and 
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fructose (79.1%). The content of the oil in dried sweet flag rhizomes was 1.20+/-
0.12%. Acorenone was dominant in the rhizomes (20.86%) followed by 
isocalamendiol (12.75%). Besides Monoterpene hydrocarbons, sequestrine ketones, 
(Trans- or Alpha) Asarone (2, 4, 5-trimethoxy-1- propenylbenzene), and Beta-asarone 
(cis- isomer) and eugenol were also identified. Some other compound identified in A. 
calamus are (-)-4-Terpineol, 2-Allyl-5-ethoxy-4-methoxyphenol, Epieudesmin, 
Lysidine, (-)-Spathulenol, Borneol, Furyl ethyl ketone, Nonanoic Acid, 2,2,5,5-
Tetramethyl-3- hexanol,Bornyl acetate, Galgravin, Retusin, (9E,12E,15E)-9,12,15- 
Octadecatrien-1-ol, Butyl Butanoate, Geranylacetate, Sakuranin, Acetic Acid, 
Camphor, Isoelemicin, á-Ursolic acid, Acetophenone, Dehydroabietic acid, 
Isoeugenol Methylether, Apigenin 4',7-dimethyl ether, Dehydrodiisoeugenol, 
Linalool, Elemicin, Linoleic acid(R. Balakumbahan et al, 2010).  
 The biochemical constituent in Vacampu is asarone. This compound has 
analgesic, sedative and neuro depressive activity which can produce sedation and 
hence reduce the irritable cry among neonates. In neonates with diarrhea, the 
spasmolytic and antisecretory effect of the extract can reduce the frequency of loose 
stools (Tanigasalam V et al, 2017).  
 Heavy Metals Analysis The content of heavy metals such as lead was present 
within the permissible limit, cadmium; mercury and arsenic were not found in the 
drug Acorus calamus (Ushakanthan et al, 2017) (table.4).  
 
Heavy Metals Analysis of Acorus calamus:   
Table 13: 
S. 
No. 
Name of the 
Element 
Results Permissible Limit 
1 Lead 0.0914 ppm 10 ppm (WHO) 
2 Cadmium Not detected 0.3 ppm (WHO) 
3 Arsenic Not detected 3 ppm (API) 
   (Ushakanthan et al., 2017) 
  The ethanolic extract of Acorus calamus significantly protects against liver 
injuries resulting in improved serum biochemical parameters such as SGOT, SGPT 
and SALP( S. Palani et al, 2009). 
 Fatty acids in Acorus calamus have palmitic acid and its ester which possess 
significant antifungal and antibacterial activity (Archana Parki, 2017). 
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 Various essential oil components present in essential oils like linalool, 1, 8-
cineol, caryophyllene, α humulene, and asarone have been reported to possess 
antioxidant activity.  
 
Uppu: 
Sodium chloride 
OuXohbi<gt<< << << <!
! gxqBh<H?!Osix<Xh<H?!gmZh<H?!uQm<Mh<H?!-zu{l<?!sLk<kqv!zu{l</!
gxqBh<hqe<!G{l<< < << < << < <!
! “lf<kl<!ohiVlzXl<!uiBUl<Ohil<kQhelil<!
! okif<kqk<k!Jbf<!okimVOli!–!sf<kkLl<!
! ng<gqeqbqe<!H]<c!nmVr<!gxqBh<hiz<!
! sqg<Ggqe<x!fQiqxr<Gr<R<!osh<H”!
 ohiVt<;<<< !
! gxqBh<hiz<!lf<kl<?!ubqx<Xh<ohiVlz<?!uiB?!ghl<!fQr<Gl</!!fQvjmh<Hk<!
kQVl</!!hsqBl<!slig<gqeqBl<!nkqgh<hMl</!
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6. BIO-CHEMICAL ANALYSIS OF  UTHAMANI KARUKKU 
 
Preparation of the extract:   
   5gms of the drug was weighed accurately and placed in a 250 ml clean 
beaker.  Then 50ml of distilled water is added and dissolved well.  Then it is boiled 
well for about 10 minutes.  It is cooled and filtered in a 100ml volumetric flask and 
then it is made to 100ml with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 
A white precepitate 
is formed 
Indicates the 
presence of 
calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
No white precipitate 
is formed 
Absence of 
sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
A white precipitate is 
formed 
Indicates the 
presence of 
chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No Brisk 
effervessence is 
formed 
Absence of 
carbonate 
5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 
No Blue colour is 
formed 
Absence of 
starch 
6.  TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of 
Ferric iron 
7. TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cynate 
solution 
Blood red colour is 
formed 
Indicates the 
presence of 
ferrous Iron. 
8.  TEST FOR PHOSPHATE 
The extract is treated with ammonium 
Molybdate and concentrated nitric acid 
No yellow 
precipitate is formed 
Absence of 
phosphate 
9.  TEST FOR ALBUMIN No Yellow Absence of 
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The extract is treated with Esbatch’s 
reagent 
precipitate is formed Albumin 
10.  TEST FOR TANNIC ACID 
The extract is treated with ferric 
choloride. 
No Blue black 
precipitate is formed 
Absence of 
Tannic acid 
11.  TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It does not  
decolourised. 
Absence of 
unsaturated 
compound 
12.  TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mins and add 8-10 drops of the extract 
and again boil it for 2 mins. 
No Colour change 
occurs. 
Absence of 
Reducing sugar 
13.  TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried well. 
Violet colour is 
formed 
Indicates the 
presence of 
Amino acid 
14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
    The extract prepared from the given sample UTHAMANI KARUKKU contains 
calcium, chloride, ferrous iron and amino acid. Biochemical Analysis report was given by  
Mrs. N.Nagaprema, M.Sc., M.Phil., Head of the Department, Biochemical Department, 
Government Siddha Medical College, Palayamkottai. 
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7. PHARMACOLOGICAL ANALYSIS 
 
ANTIDIARRHOEAL ACTIVITY OF UK 
 
  Castor Oil-Induced Diarrhea in rats. This test was done based on the method 
used by Awouters et al.24 rats were fasted for 18 hours and divided into four groups 
with six animals in each group. The first group received distilled water (10ml/kg) and 
the second group received loperamide (3mg/kg), serving as negative and positive 
controls, respectively. Groups 3&4 received 100, 200mg/kg of the uthamani karukku 
medicine, respectively. After one hour, all the animals received 0.5ml/animal of 
castor oil orally. The animals were kept in separate metabolic cages. The severity of 
diarrhea was assessed for 4 hours. The mean total number of feces (dry and wet 
diarrheal droppings) was determined and compared with the negative control group. 
The total score of diarrheal feces for the negative control group was considered as 
100%. The percent inhibition of total defecation and that of diarrhea were calculated 
using the following formulas:  
% inhibition of defecation 
= Total number of feces in the negative control − Total number of feces in treated group 
    Total number of feces in the negative control   × 100, 
% inhibition of diarrhea 
= Total number of diarrheal feces in the negative control − Total number of diarrheal feces TG  
   Total number of diarrheal feces in the negative control × 100. 
Table 14: 
Groups Dose (mg/kg) 
Onset of 
diarrhea 
(min) 
Total 
number of 
feces 
% 
inhibition 
of 
defecation# 
Weight of 
stool(g) 
Total 
number 
of 
diarrheal 
feces 
% 
inhibition 
of 
diarrhea 
Group 1 
(negative 
control) 
- 61±2.48 20.68±0.76 - 0.51±0.21 8.67±0.66 - 
Group 2 
(positive 
control ) 
3 180±7.45 6.87±0.05 66.78 0.35±0.01 2.33±0.23 73.12 
Group 
3(extract) 200 180±0.33 15.00±0.01 27.47 0.56±0.12 4.81±0.40 44.52 
Group 4 
(extract) 400 82±0.41 8.02±0.78 61.22 0.44±0.20 3.43±0.10 60.44 
 
  Castor oil has been widely used for induction of diarrhea in antidiarrheal 
activity studies because it releases ricinoleic acid, a metabolite that causes diarrhea, 
upon metabolism in the gut. Ricinoleic acid initiates diarrhea v
irritation of GI mucosa, leading to the release of prostaglandin which stimulates 
gastrointestinal motility and electrolyte secretion, reducing electrolyte absorption 
from the intestine and colon; these are similar to the pathophysiol
resulting in diarrhea. Therefore, the antidiarrheal activity of the plant might be due to 
the activities that oppose the actions of castor oil for induction of diarrhea or 
pathophysiologic processes leading to diarrhea. The extract has been 
decrease the intestinal fluid accumulation. This suggests that the plant extract may 
decrease water and electrolyte secretion to the intestinal lumen while promoting their 
absorption, which in turn could decrease intestinal overload and distension
a decrease in intestinal motility (giving a longer time for absorption) and water 
contents of the fecal drops and hence overall reduction in the total number of 
defecation instances and diarrheal drops in treated groups. This is consistent wit
mechanism of action of loperamide for its antidiarrheal effect as presented in the 
literatures. In addition, the extract may have an anticholinergic activity and cause 
reduction in intestinal motility and secretion, which is in agreement with the act
atropine on the intestine
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RESULT: 
 A significant reduction in the number of defecation instances was observed 
with all the test doses of the extract compared with the negative control group. The 
mean total number of defecation instances in extract-treated groups was 12 ± 0.93, 
and at 100, 200 mg/kg doses of the extract, respectively, while this value was in the 
loperamide-treated group. The percent inhibition of total defecation relative to the 
negative control group was 27.47%, 61.22%at 100, and 200 mg/kg doses of the 
extract, respectively. The standard drug had shown a more marked reduction in the 
number of defecation instances (71.12%) compared to the vehicle-treated group. The 
mean number of diarrheal drops in the extract-treated groups was, and at 100, 
200,mg/kg doses, respectively, while in the loperamide-treated group it was. Percent 
inhibition of wet (diarrheal) feces was, 44.52%, 60.44% and at the doses of 100, 200. 
The percent inhibition of diarrhea recorded for the loperamide-treated group was 
73.12 
 
DISCUSSION: 
 Diarrhea is caused by four pathophysiologic processes: increased luminal 
osmolarity, electrolytes secretion, decreased electrolytes absorption, and abnormal 
intestinal motility causing reduction in intestinal transit time. In the intervention of 
diarrhea, antimotility and antisecretory agents remain as the main agents used to 
decrease 
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ANTIPYRETIC ACTIVITY OF UK 
 
MATERIALS AND METHODS 
Experimental Animals  
  Wistar albino rats of either sex weighing about 150-200g were employed for 
this study. They were procured from Kalasalingam college of Pharmacy, 
srivilliputhurand maintained on the suitable nutritional and environmental condition 
throughout the experiment. They were housed in polypropylene cages with paddy 
house bedding under standard laboratory condition for an acclimatization periods of 7 
days prior to performing the experiment. 
 
Experimental Design  
Protocol 
  Body weights of the animals were recorded and they were randomly divided 
into 5 groups of 6 animals each as follows: 
Group I  :  animals served as control  
Group II  :  animals were treated with yeast via subcutaneous   injection  
  (10ml/kg).  
Group III  :  animals were administered with yeast (10 ml/kg) and the  
   standard drug paracetamol (150mg/kg b.w.), orally  
Group IV  :  animals were administered with yeast (10ml/kg,) and with  
   UK (100mg/kg b.w.), orally.  
Group V  :  animals were administered with yeast (10ml/kg,) and with  
      UK (200mg/kg b.w.), orally.   
Yeast induced pyrexia  
  Pyrexia was induced by subcutaneous injection of 20 % w/v of brewer’s yeast 
(10ml/kg) in distilled water. Basal rectal temperature was measured before the 
injection of yeast, by inserting digital clinical thermometer to a depth of 2 cm into the 
rectum.  
  The rise in rectal temperature was recorded 19 h after yeast injection. 
Paracetamol 150mg/kg body weight was used as the standard antipyretic drug. Rectal 
temperature of animals was noted at regular intervals following the respective 
treatments. The temperature was measured at 1st, 2nd, and 3rd hour after drug 
administration. 
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Statistical Significance  
  The statistical analysis was done by ANOVA followed by Dunnet’s test for 
multiple comparisons. P < 0.01 was considered significant in the experiment. 
 
RESULT 
Effect of aqueous and ethanol extracts of uthamani karukku on body 
temperature in   yeast induced pyrexia 
Table 15: 
Groups 
Rectal Temperature in 0C after 18hrs of Yeast Injection 
0 hr 1hr 2hr 3hr 
Group I 37.50±0.01 37.70±0.22 37.90±0.32 37.80±0.60 
Group II 41.50±0.22 39.90±0.20 38.72±0.64 38.12±0.72 
Group III 40.63±0.18 38.12±0.15 38.01±0.22 37.02±0.28 
Group IV 40.64±0.02 39.50±0.18 39.02±0.64 38.62±0.16 
Group V 40.51±0.21 39.18±0.17 38.04±0.20 37.68±0.15 
 
Values are expressed as Mean ±SEM.   n = 6 in each group, “*” indicate P < 0.01 
compared to control 
 
DISCUSSION 
 Fever is a complex physiologic response triggered by infections or aseptic 
stimuli. Elevation in body temperature occurs when the concentration of 
prostaglandin E2 (PGE2) increases within parts of the brain. Such an elevation 
contributes to a considerable alteration in the firing rate of neurons that control the 
thermoregulation process in the hypothalamus. It is now evident that most of the 
antipyretic drugs exert their action by inhibiting the enzymatic activity of 
cyclooxygenase and consequently reducing the levels of PGE2 within the 
hypothalamic region. A natural antipyretic agent with reduced or no toxicity is 
therefore, essential.  
 Since antipyretic activity is commonly mentioned as a characteristic of drugs 
or compounds, which have an inhibitory activity on prostaglandins biosynthesis, the 
yeast induced hyperpyrexia in rat model was employed to investigate the antipyretic 
activity of the extract. Yeast induced pyrexia is called pathogenic fever which is due 
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to the production of prostaglandins (PGE2) which set the thermoregulatory centre at a 
higher temperature.   
 The HIGH DOSE PE showed more pronounced effect in lowering the 
hyperthermia than the LOW DOSE PE, but found to have similar effect as the 
standard drug Paracetamol at 3rd hour of administration. The extracts are likely to 
reduce pyrexia by reducing brain concentration of prostaglandin E2 especially in the 
hypothalamus through its action on COX-3 or by enhancement of the production of 
the body’s own antipyretic substances like vasopressin and arginine.   
  Antipyretics have been shown to suppress fever by inhibiting prostaglandin 
synthetase, resulting in the blockade of the synthesis of prostaglandin in the brain or 
suppressing the rise of interleukin1α production subsequent to interferon production. 
 
CONCLUSION  
 In conclusion, this study provides evidences for the antipyretic activity of UK 
which could partly contribute to its ethno medical use. However, further investigation 
is required to isolate the active constituents responsible for these activities and to 
elucidate the exact mechanisms of action. 
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF  
Effect of Acute Toxicity Study (14 Days) of UTHAMANI KARUKKU 
Physical and behavioral examinations. 
Table 16 
Group no. Dose(mg/kg) Observation sign No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Home cage activity 
Table 17 
Functional 
and 
Behavioural 
observation 
Observation 
5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 Female n=3 Female n=3 Female n=3 
Body position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
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 Hand held observation 
Table 18 
Functional 
and 
Behavioral 
observation 
Observation 
Control 
5 mg/ 
kg 
(G-I) 
50 
mg/kg 
(G-II) 
300 
mg/kg 
(G-III) 
1000 
mg/kg 
(G-IV) 
2000 
mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Mortality 
Table 19 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
UTHAMANI KARUKKU at a dose of 2000 mg/kg to the rats do not produce drug-
related toxicity and mortality. So No-Observed-Adverse-Effect- Level (NOAEL) of 
UTHAMANI KARUKKU is 2000 mg/kg. 
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DISCUSSION 
  UTHAMANI KARUKKU was administered single time at the dose of 5mg/kg, 
50mg/kg, 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for consecutive 
14 days after administration. Doses were selected based on the pilot study and 
literature review. All animals were observed daily once for any abnormal clinical 
signs. Weekly body weight and food consumption were recorded. No mortality was 
observed during the entire period of the study. Data obtained in this study indicated 
no significance physical and behavioural signs of any toxicity due to administration of 
UTHAMANI KARUKKU at the doses of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg 
and 2000mg/kg to rats.  
  
 At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups. Food consumption of all treated animals was found normal as compared to 
normal group. 
  Body weight at weekly interval was measured to find out the effect of 
UTHAMANI KARUKKUon the growth rate. Body weight change in drug treated 
animals was found normal. 
 
INTERPRETATION: 
 UTHAMANI KARUKKUwas administered single time at the dose of 5mg/kg, 
50mg/kg, 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for consecutive 
14 days after administration. Doses were selected based on the pilot study and 
literature review. All animals were observed daily once for any abnormal clinical 
signs. Weekly body weight and food consumption were recorded. No mortality was 
observed during the entire period of the study. Data obtained in this study indicated 
no significance physical and behaviou ral signs of any toxicity due to administration 
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of  UTHAMANI KARUKKU at the doses of 5mg/kg, 50mg/kg, 300mg/kg, 
1000mg/kg and 2000mg/kg to rats.  
 At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups. Food consumption of all treated animals was found normal as compared to 
normal group. 
 Body weight at weekly interval was measured to find out the effect of 
UTHAMANI KARUKKUon the growth rate. Body weight change in drug treated 
animals was found normal. 
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SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF UTHAMANI KARUKKU 
EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF UTHAMANI KARUKKU ON 
BODY WEIGHT IN GRAM 
Table 20 
GROUP CONTROL LOW  MID HIGH 
1st day 122.3±1.03 125±1.543 124.3±2.231 126.3±2.23 
7th day 132.3±1.03 131.3±1.343 131±2.113 137±2.11 
14th day 134.1±1.004 102.3±1.12 102.4±2.012 103.4±2.012 
21st day 103.3±2.120 110.2±1.501 104±1.131 105±1.13 
28th day 113.3±1.041 112.3±1.202 143±2.0405 146±2.040 
 
 Values are expressed as mean ± SEM Statistical significance (p) calculated by 
one way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group. 
 
EFFECT OF SUBACUTE DOSE (28 DAYS) OF UTHAMANI KARUKKU 
 ON ORGAN WEIGHT (PHYSICAL PARAMETER) IN GRAM 
Table 21 
GROUP CONTROL LOW  MID HIGH 
HEART 0.73±0.02 0.54±0.04 1.31±0.11 0.71±0.02 
LIVER 2.61± 0.23 2.63±0.23 2.50±0.01 2.53± 0.23 
LUNGS 1.61±0.10 0.61±0.14 0.80±0.24 1.73±0.10 
KIDNEY L 0.73±0.02 1.82±0.03 0.73±0.02 0.71±0.02 
 R 0.71±0.024 1.44±0.02 0.71±0.024 0.72±0.024 
 
 Values are expressed as mean ± SEM Statistical significance (p) calculated by 
one way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF UTHAMANI KARUKKU ON 
HAEMATOLOGICAL PARAMETERS 
Table 22 
Drug 
treatm
ent 
RBC 
millio
n 
cells/c
mm 
WBC  
cells/cm
m 
Haemoglo
bingm % 
        Differential count% 
Neutro
phils 
Eosino
phils 
Mono
cyte 
Lympho
cyte 
Contr
ol 
6.51±0
.40 
6255.41±
23.32 17.40±0.45 
34.27±1
.20 
1.83±0.
11 
0.75±0
.15 
26.13±3.
32 
LOW  5.77±0
.20 
5337.04±
23.22 17.20±0.43 
28.54±1
.41 
2.40±0.
14 
0.42±0
.30 
26.22±3.
51 
MID 4.63±0
.21 
6307.25±
32.35 17.11±1.03 
33.32±2
.22 
1.74±0.
12 
0.62±0
.40 
26.13±3.
32 
HIGH 5.56±0
.21 
6691.25±
32.35 17.11±1.03 
31.32±2
.22 
1.80±0.
12 
0.64±0
.40 
27.13±3.
32 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
 
EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF UTHAMANI KARUKKU ON 
BIOCHEMICAL PARAMETERS 
Table 23: 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT 
(IU/L) 
ALP 
(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 45.14±3.02 14.24±4.31 246.12±11.32 38.35±3.00 0.57±0.03 
      LOW 45.13±3.22 14.23±4.01 254.11±12.42 43.53±2.42 0.53±0.04 
MID 43.21±4.44 14.31±2.21 248.45±4.14 42.12±2.22 0.48±0.04 
HIGH 45.21±4.44 14.31±2.21 237.45±4.14 43.12±2.22 0.49±0.04 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF UTHAMANI KARUKKU ON 
FOOD INTAKE IN GRAM 
Table 24: 
GROUP CONTROL Low mid high 
1st DAY 21.33±13.5110 22.1672±14.3 15.10±21.71 20.5±7.62 
7th DAY 18.5±11. 13.863±12.67 19.73±9.853 14.17±14.41 
14th DAY 21.83±8.72 13.83±14.28 13±13.96 22.72±8.981 
21st DAY 14.87±12.4 18±8.466 18.88±9.43 22.17±8.02 
28th DAY 15.10±11.38 21.38±11.50 13±8.90 13±7.57 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
 
Effect of Sub- Acute Dose (28 Days) Of  UTHAMANI KARUKKU On Water 
Intake in ml 
Table 25 
GROUP CONTROL 
UK  
(200mg/kg) 
UK 
(400mg/kg) 
UK 
(600mg/kg) 
1st DAY 98.3338±13.5110 89.1672±14.3426 102.10±21.7199 67.5±7.6203 
7th DAY 85.5±11.7938 100.863±12.6770 76.6673±9.85363 81.6717±14.4150 
14th 
DAY 
58.3383±8.72817 90.8363±14.2812 80±13.9692 89.1672±8.88981 
21st DAY 91.6687±12.4949 85±8.46662 65.8338±9.43550 89.1717±8.79602 
28th 
DAY 
82.10±11.3840 88.3348±11.5004 80±8.90061 70±7.57773 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group 
 
61 
 
EFFECT OF SUB ACUTE DOSES (28 DAY) OF UTHAMANI KARUKKU ON 
ELECTROLYTES: - 
Table 26 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); NS- non-significant, *p<0.05, **p<0.01, 
***p<0.001,  
 
RESULTS: 
CLINICAL SIGNS: 
 All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
 All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
 Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period of 
28 days. 
Food consumption: 
 During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
  
GROUP CONTROL 
UK 
(200mg/kg) 
UK 
(400mg/kg) 
UK 
(600mg/kg) 
Sodium (mg/dl) 124.00±0.5 114.40±0.62 120±0.71 121.70±0.40 
Calcium(mg/dl) 6.80±0.189 8.24±0.783*** 6.7±0.99*** 6.10±0.11*** 
Phosphorus 
(U/L) 
6.258±0.07 5.30±0.05ns 6.30±0.091ns 5.7±0.32* 
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Organ Weight: 
 Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.21. Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
 The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls; however, the increase or decrease in the 
values obtained was within normal biological and laboratory limits or the effect was 
not dose dependent. 
Biochemical Investigations: 
 Results of Biochemical investigations conducted on the day 29th and recorded 
in Table no 22, 23 revealed the following significant changes in the values of hepatic 
serum enzymes studied. When compared with those of respective control. However, 
the increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
INTERPRETATION: 
1. All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2. No signs of toxicity were observed in animals from different dose groups  during 
the dosing period of 28 days. 
3. Animals from all the treated dose groups exhibited comparable body weight  gain 
with that of controls throughout the dosing period of 28 days. 
4. Food consumption of control and treated animals was found to be comparable  
throughout the dosing period of 28 days 
5. Hematological analysis conducted at the end of the dosing period on day 29th,  
revealed no abnormalities attributable to the treatment. 
6. Biochemical analysis conducted at the end of the dosing period on day 29th, no  
abnormalities attributable to the treatment. 
7. Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable with that of respective controls. 
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8. ANTIMICROBIAL ACTIVITY 
Aim 
 To study the Anti-microbial action of “Uthamani Karukku” against  
Streptococcus Pneumoniae, Pseudomonas aeruginosae, Escherichia coli, Klebsiella 
Pneumoniae 
Medium 
Mueller Hinton agar. 
Components of medium  
Beef extract   - 300gms/lit 
Agar    - 17 gms/lit 
Starch    - 1.5 gms/lit 
Casein Hydroxylate  - 17.5 gms/lit 
Distilled water  - 1000 ml 
PH    - 7.6 
Procedure 
 The media was prepared from the above components and poured and dried on 
a petri dish. The organism was streaked on the medium and the test drug (1gm drug in 
250ml of water) was placed on the medium. This is incubated at 37°C for one over 
night and observed for the susceptibility shown up clearance around the drug. 
Result: 
  The test drug Uthamani Karukku was resistant against  Streptococcus 
Pneumoniae, Pseudomonas aeruginosae, Escherichia coli, Klebsiella Pneumoniae 
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9. RESULTS AND OBSERVATIONS 
 
Results of the study were observed with respect to the following criteria. 
1. Age  
2. Sex  
3.  Paruvakaalam  
4. Diet 
5. Distribution of lands  
6. Mukkutram  a) vatham b) pitham c) kabam  
7. Udarthathukkal  
8. Envagai thervu 
9.  Etiological factors  
11. Majority symptoms  
12. Symptoms relieved within  a) 1-2 days b) 3-5 days c) 6-12 days 
13. Bristol Stool Chart assessment 
14. Dehydration assessment 
For this study 20 In-patients and 22 Out-patients were selected 
 
 
                                                                                                                         
  
 S.No. Age 
1 
1-3 
years 
Thalaparuvam, sappani, mutham and 
2 
4-6 
years 
Ampuli, sitril, siruparai, siruthaer(male 
Ammanai, neeraduthal, oonjal(female child)
3 
7-12 
years Pethai and 
  
 
 
Inference:  
  Therefore the above table indicates that children under the age group of 1
years (80.9%) are mostly affected.
 
                                                         
 
Thalaparuvam, sappani, mutham and varugai
Ampuli, sitril, siruparai, siruthaer(male child)       
Ammanai, neeraduthal, oonjal(female child)         
Siruparuvam(male child)       Pethai and 
pethumbai(female child)
1-
3 
ye
a
rs
4-
6 
ye
a
rs
7-
12
 
ye
a
rs
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Age distribution 
 
Table 27 
Paruvam No. of 
varugai 
child) 
 
Siruparuvam(male child) 
pethumbai(female child) 
Figure 9 
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Sex distribution 
Table 28: 
 
S.No. Sex 
No. of cases 
( out of 42) Percentage% 
1 Male 16 39% 
2 Female 26 61.9% 
 
 
 
Figure 10 
 
Inference:  
  Among 42 cases of study 16 were males (39 %) and 26 were females (61.9%). 
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Distribution of Paruvakaalam 
Table 29: 
S. 
No. 
Paruvakaalam No. of cases Percentage 
1 Kaarkaalam(Aavani, puratasi) 3 7% 
2 Koothirkaalam(Aipasi, Karthigai) 1 2.30% 
3 Munpani(Maargazhi, thai) 4 9.50% 
4 Pinpani(Maasi, panguni) 16 38% 
5 Ilavaenir(Sithirai, vaigasi) 12 28.50% 
6 Muthuvaenir(Aani, aadi) 6 14.20% 
 
 
KAALANGAL
Kaarkaalam(Aavani, puratasi)
Koothirkaalam(Aipasi, Karthigai)
Munpani(Maargazhi, thai)
Pinpani(Maasi, panguni)
Ilavaenir(Sithirai, vaigasi)
Muthuvaenir(Aani, aadi)
 
Figure 11 
 
Inference:  
  Among 42 cases of study 16 (38%) were attended OP & IP at Elavenil Kaalam 
 
 
 
 
 
 
  
 
S.No. 
1 Vegetarian
2 Non
3 Lacto
 
Inference:  
  Among 42 cases of study 18 were
(55%) and 1 is lacto vegetarian (2%).
 
 
 
Vegetarian
42.80%
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Diet 
Table 30 
Diet No. of cases Percentage
 18 
-Vegetarian 23 
- Vegetarian 1 
 
DIET 
Figure 12 
 vegetarian (43 %), 23 were Non
 
 
Non-Vegetarian Lacto-
Vegetarian
54.70%
2%
 
42.80% 
54.70% 
2% 
 
- vegetarian 
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DISTRIBUTION OF LANDS 
Table 31 
S. NO. THINAI 
    NO. OF CASES 
      (OUT OF 42) 
PERCENTAGE 
   (%) 
1.       Kurinji (mountain)  2 4% 
2. Mullai(forest) 0 0% 
3. Marutham  (flat fertile land) 40 89% 
4. Neithal (sea and sea shore) 0 0% 
5. Pallai (desert) 0 0% 
 
 
4%
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0% 0%0
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Figure 13 
Inference:  
  According to siddha concept, no disease occurs to the people living in 
marutham. Incidence of disease in marutha nilam was due to altered life style and 
environment. The study was conducted in and around Tirunelveli which has all the 5 
lands but majority patients came within limit of marutham land. 
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MUKKUTRA THEORY: 
Table 32: 
  
 
Figure 14 
Inference:  
  In vatham all the cases had derangement of abhanan and kirugaran. 
 
 
0 20 40 60 80 100
Pranan
Abhanan
Vyanan
Uthanan
Samanan
Naagan
Koorman
Kirugaran
Devathathan
Dhanajeyan
Percentage(%)
No.of cases(out of 42)
S. NO. 
TYPES OF 
VATHAM 
NO. OF CASES 
(OUT OF 42) 
PERCENTAGE 
(%) 
1 Pranan 14 33.33 
 Abhanan 40 95.23 
3 Vyanan 2 4.76 
4 Uthanan 2 4.76 
5 Samanan 7 16.66 
6 Naagan 0 0 
7 Koorman 0 0 
8 Kirugaran 30 71.42 
9 Devathathan 12 28.57 
10 Dhanajeyan 0 0 
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Table 33 
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8
5
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Figure 15 
 
 
Inference  
  In pitham all the cases  had derangement of analam. 
 
 
 
 
 
 
S. NO. 
TYPES OF 
PITHAM 
NO. OF CASES 
(OUT OF 42) 
PERCENTAGE 
(%) 
1 Analam 40 95.23 
2 Ranjagam 8 38.05 
3 Saathagam 5 11.90 
4 Alosagam 8 19.04 
5 Prasagam 0 0 
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Table 34: 
S.NO. 
TYPES OF 
KAPAM 
NO. OF CASES 
(OUT OF 42) 
PERCENTAGE 
(%) 
1 Avalambagam 40 95.23 
2 Kilethagam 40 95.23 
3 Pothagam 12 28.57 
4 Tharpagam 30 71.42 
5 Santhigam 0 0 
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Figure 16 
Inference  
  In kabam all the cases  had derangement of avalambagam and kilethagam. 
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Table 35: 
S.NO UDARTHATHUKAL 
NO.OF 
PT NO.OF PERCENTAGE 
1 Saaram 42 100.00% 
2 Senneer 8 19% 
3 Oon 30 71% 
4 Koluppu 30 71.00% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 Sukkilam 0 0% 
8 Total 42 100% 
 
 
38%
7%
28%
27%
0% 0% 0%
UDARTHATHUKAL
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3 OON
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Figure 17 
Inference:  
  In Ezhu udalthathukal 100% of the cases had derangement of Saaram and 71% 
had derangement of Oon and koluppu.  
 
 
 
 
 
 
 S.NO ENVAGAI THERVU
1 
2 
3 
4 
5 Sparisam
6 
7 
8 Moothiram
9 
 
Inference:  
  In envagai thervu  na, sparism, malam were affected in majority of cases
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Table 36 
 NO.OF.PT PERCENTAGE
Naa 32 
Niram 10 
Mozhi 2 
Vizhi 12 
 30 
Naadi 0 
Malam 40 
 4 
Total 42 
Figure 18 
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Table 37 
S.NO ETIOLOGICAL FACTORS NO.OF PT PERCENTAGE 
1 Milk protein allergy 8 19% 
2 Climate change 6 14% 
3 Poor hygeine 10 23% 
4 Antibiotic history 3 7.14% 
5 Hotel food 6 14% 
6 Unknown 4 9.52% 
7 Others 5 11.90% 
8 Total 42 100% 
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Figure 19 
 
Inference:  
  From the above table it is evident that intake of poor hygiene, milk protein 
allergy, climate change are the main cause of Kana mantham. Antibiotic history also 
has an important role in causing AGE. Others mostly may be due to infectious cause. 
 
  
  
S.NO MAJORITY SYMPTOMS
1 Diarrohea
2 Bloating abdomen
3 Fever
4 Watery nasal discharge
5 Cough
6 Headache
7 Drowsiness
8 Total
 
 
Inference:  
  Patients were selected with  
diarrhoea (95%), bloating abdomen (90%), watery nasal discharge and fever are most 
commonly recorded. 
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Table 38: 
 NO.OF PT PERCENTAGE
 40 95%
 38 90%
 12 28%
 30 71%
 14 33%
 1 2.38%
 0 
 42 100%
Figure 20 
Maximum  of  three symptoms among that 
 
 
 
 
 
 
 
0% 
 
 
NO.OF.PT
PERCENTAGE
  
 
 
S. 
NO. 
SYMPTOMS RELIEVED WITHIN  1
1 
2 Bloating abdomen
3 
4 Watery nasal discharge
5 
6 
 
 
 
Inference:  
  In 50% of cases diarrhoea symptom relieved within 1 
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Table 39: 
-
2 DAYS 
NO. OF 
CASES 
Diarrhea 21 
 8 
Fever 4 
 4 
Cough 0 
Headache 0 
Figure 21 
to 2 days.
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Inference:  
  In 28.5% of cases diarrhoea symptom relieved within 3 
 In 60% of cases bloating abdomen symptom relieved within 3
In 47.6% of cases watery nasal discharge symptom relieved within 3 
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Table 40 
-
5 DAYS 
NO. OF CASES 
Diarrhea 12 
 25 
Fever 5 
 20 
Cough 2 
Headache 1 
Figure 22 
to 5 days.
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S. NO. 
SYMPTOMS 
RELIEVED WITHIN  6
1 
2 Bloating abdomen
3 
4 Watery nasal discharge
5 
6 
  
 
Inference:  
  In 16.6% of cases diarrhoea symptom relieved within 6 to 12 days
In 12% of cases bloating abdomen symptom relieved within 6 to 12 days.
In 14% of cases watery nasal discharge symptom relieved within 6 to 12 days.
In 7% of cases fever symptom relieved within 6 to 12 days.
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Table 41 
-
12 DAYS 
NO. OF CASES 
Diarrhea 7 
 5 
Fever 3 
 6 
Cough 0 
Headache Nil 
Figure 23 
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BRISTOL STOOL CHART ASSESSMENT: 
 
Table 42: 
S. No. BRISTOL STOOL CHART (BSC) NO. OF CASES 
1 Type 1 0 
2 Type 2 0 
3 Type 3 2 
4 Type 4 0 
5 Type 5 8 
6 Type 6 12 
7 Type 7 20 
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BRISTOL STOOL CHART
No. of cases
 
Figure 24 
Inference: 
           Type 7- Liquid consistency with no solid pieces indicates severe diarrhea 20 
cases had this type stool consistency. 
           Type 6- Mushy consistency with ragged edges indicates mild diarrhea 12 cases 
had this type of stool consistency. 
          Type 5- Soft blobs with clear cut edges indicate fibre lacking diet 8 cases had 
this type of stool frequency. 
          Type 3- A sausage shape with cracks in the surface is normal stool but the 2 
cases have increased frequency max 5 times per day and hence treated with 
medication. 
  
   S. NO. 
   DEHYDRATION 
ASSESSMENT
1 Minimal/none
2 Mild/moderate
3 
 
 
Inference: 
           Minimal dehydration 57% of cases recorded.
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DEHYDRATION ASSESSMENT 
Table 43: 
 
   NO. OF CASES    
 16 
 24 
Severe 2 
Figure 25 
 
38%
57%
5%
DEHYDRATION ASSESSMENT
Minimal/none Mild/moderate Severe
PERCENTAGE 
38% 
57% 
4.7% 
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OUT PATIENTS RECORD 
 
Table 44 
S. NO. OP. NO. NAME AGE/ SEX NO. OF DAYS 
1 9780 Jerlin 3/Fch 14 
2 10429 Vijayamari 4/Fch 5 
3 17293 Sri athi lakshmi 2/Fch 12 
4 18073 Sajiya 1 ½/Fch 3 
5 24032 Rajesh 4/Mch 5 
6 35919  Kanishka 1½/Fch 5 
7 76619 Manishram 1/Mch 7 
8 38963 Mohammed 1½ /Mch 5 
9 45054 Miruthula 1 /Fch 3 
10 52076 Nafeela 1 /Fch 11 
11 54896 Asna Ameera 3/Fch 3 
12 67132 Miruthla 1/Fch 4 
13 67133 Hasna 3/Fch 4 
14 36821 Ishai sri 2/Fch 4 
15 70632 Gajendra Nathan 21/4/Mch 3 
16 77585 Mirnalini 1/Fch 2 
17 16691 Aran 1½/Mch 3 
18 23965 Bhairav perumal 1 /Mch 7 
19 25910 Sivani 1/Fch 3 
20 32102 Rupashree 3/Fch 4 
21 43647 Joshua johin 7/Mch 4 
   22    67107 Athinya 1/Fch     3 
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INPATIENTS RECORDS 
Table 45: 
S.No IP.No      Name Age /sex Address Signs/symptoms 
Admission 
date 
Discharge 
date 
No .of 
days 
treated 
1 2293 Yaksha 1Fch Sriram nagar, T nagar, Tirunelveli 
Diarrhea, loss of 
appetite, bloated 
abdomen 
6.9.18 12.9.18 7 
2 208 Bhairav perumal 1mch 5/55, Mkp nagar palayamkottai 
Diarrhea, Mild fever, 
bloated abdomen, loss 
of appetite 
31.1.19 3.2.19 4 
3 233 Prasanna 11/2mch 6/3, thayapuram theru, nellai 
Diarrhea, bloated 
abdomen, loss of 
appetite. 
2.2.19 6.2.19 7 
4 544 Joshua 2mch 6/85, kasthuribhai st, palayamkottai Diarrhea, loss of 
appetite, weight loss 2.3.19 7.3.19 6 
5 540 I  shwarya 8fch 11, church street, kulavanigarpuram, Tirunelveli 
Diarrhea, fever, 
cough, abdominal 
pain 
2.3.19 8.3.19 7 
6 627 Isai   yazhini 1Fch 5/115, main road, puliyangudi 
Fever, Cough,watery 
nasal discharge, 
abdominal pain 
8.3.19 13.3.19 6 
7 661 Nihana 11/2fch  62A, Ganesapuram , melapalayam, Tirunelveli 
Diarrhea, cough, 
watery nasal 
discharge 
14.3.19 23.3.19 10 
8 792 Vithula 1fch 
90, siva bhagavathi illam, Nehru st,  
Tirunelveli 
 
Diarrhea, abdominal 
distension, watery 
nasal discharge 
 
27.3.19 2.4.19 7 
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9 827  Hariharan 11/2mch 9/1, Krishnan west st, tirunelveli 
Diarrhea, abdominal 
distension, fever, 
water nasal discharge 
30.3.19 4.4.19 6 
10 885 Mahadishri 1 fch R. C church street, puliyangudi 
Watery nasal 
discharge, abdominal 
distension, diarrhea, 
vomiting 
5.4.19 11.4.19 7 
11 870 Edith gavriella 4fch 1139, ATK nagar, ktc nagar, Tirunelveli 
Diarrhea, vomiting, 
loss of appetite, 
weight 
loss,abdominal pain 
3.4.19 11.4.19 9 
12 891 Samsul alha 6mch 4/45, kodiswaran nagar, 2
nd
 main road, 
nellai 
Diarrhea, watery 
nasal discharge, 
cough, abdominal 
pain 
6.4.19 13.4.19 8 
13 938  Thangavel 
murugan 1mch 
52/35, guru nathapuram, puthu theru, 
tirunelveli 
Watery nasal 
discharge, fever, 
cough.  
15.4.19 22.4.19 8 
14 943  Akshya muthu 21/2fch No. 6, munai alwar st, palayamkottai 
Diarrhea, watery 
nasal discharge, 
periumblical pain. 
15.4.19 18.4.19 4 
15 1103 Ponmathi sahana 3fch 201/7b,muragankuruchi,palayamkottai 
Diarrhea, loss of 
appetite, abdominal 
distension 
1.5.19 5.4.19 5 
16 1167  aakash 2mch 26, bharadawa st, palayamkottai 
Abdominal 
distension, vomiting, 
diarrhea, watery nasal 
discharge 
8.5.19 13.5.19 6 
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17 1205 Darith bella 3fch 1139, ATK nagar, ktc nagar, nellai 
Abdominal 
distension, cough, 
watery nasal 
discharge, abdominal 
pain 
11.5.19 15.5.19 5 
18 1230 Karunesh raj 4mch l/1 therku theru, vengala pottal, 
maanur, tirunelveli 
Abdominal 
distension, diaarhea. 14.5.19 19.5.19 6 
19 1339 mohammed 1mch 14, mohammed ali st, tirunelveli Diarrhea, abdominal distension 24.5.19 31.5.19 8 
20 1356  Ashwathika sri 3fch 328/15, Lks palayam, thenkasi 
Diarrhea, bloating 
abdomen, fever, 
watery nasal 
disacharge. 
27.5.19 4.6.19 8 
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LABORATORY INVESTIGATIONS 
BT – Before Treatment,   AT -  After Treatment, P – Polymorphs,  L – Lymphocytes, E-Eosionophils,   ESR – Erythrocyte Sedimentation 
Rate, Hb - Haemoglobin A- Albumin, S – Sugar, D – Deposits, NR- Non Reactive, NW – Not Willing 
Table : 46 
S.No. OP/IP No. 
Name of the 
patient 
Haematological Investigation Motion Analysis 
WBC Total 
Count cells /  
cu.mm 
WBC differential count ESR – mm/ Hr 
Hb gm% 
Before Treatment After Treatment 
BT AT BT AT 
Ova Cyst Culture Ova Cyst Culture 
BT AT P% L% E% P% L% E% 1hr 1hr BT AT 
1  52076 Nafeela 7000 6000 58 25 1 58 25 1 NR NR 11 11 NIL NIL NIL NIL NIL NIL 
2  10429 Vijayamari 10400 7000 58 27 5 57 25 3 8 8 10.7 11 NIL NIL NIL NIL NIL NIL 
3  17293 Sri Aathi 
lakshmi 
5800 10000 48 46 6 42 54 4 27 38 5.3 7.6 NIL NIL NIL NIL NIL NIL 
4  36821 Ishai sri 8000 NW 67 30 3 NW NW NW 10 NW 10.4 NW NIL NIL NIL NW NW NW 
5  43647 Joshua Johin 8100 NW 60 35 4 NW NW NW 10 NW 11.6 NW NW NW NW NW NW NW 
6  54896 Asna Ameera 8000 NW 54 30 1 NW NW NW NR NR 11.9 NW NW NW NW NW NW NW 
7  1103 Ponmathi 
sahana 
8000 NW 56 34 10 NW NW NW 26 NW 9.2 NW NIL NIL NIL NW NW NW 
8  540 Ishwarya 6500 NW 54 44 2 NW NW NW 22 NW 10 NW NIL NIL NIL NW NW NW 
9  661 Nihana 10000 9000 50 45 5 49 42 2 NR NR 9.2 10 NIL NIL NIL NIL NIL NIL 
10  938 Thangavel 
murugan 
7400 NW 50 48 2 NW NW NW NR NR 10.3 NW Present Present E.coli NIL NIL NIL 
11  891 Samsul alha 7000 NW 53 31 6 NW NW NW 12 NW 7.8 NW NIL NIL No 
growth 
NIL NIL NIL 
12  943 Akshya 
muthu 
7400 NW 68 29 3 NW NW NW NR NW 13.4 NW NW NW NW NW NW NW 
13  1167 Akash 7000 NW 41 54 5 NW NW NW 6 NW 11.5 NW NW NW NW NW NW NW 
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10. DISCUSSION 
  Kana maantham is a pediatric problem; the clinical features are more are less 
compared with Acute Gastro Enteritis. The various dimensions of the trial work are 
discussed below. 
  In this study 22 cases were treated at the Out-Patient post graduate department 
and 20 cases were treated at the In-Patient ward. Siddha methods of diagnosis were 
carried out and recorded in the selection proforma, and the diagnosis was confirmed 
with the help of modern investigations. The Patients were treated with drug Uthamani 
karukku and clearly observed. The observations were discussed here under.  
1. Distribution according to Age:  
 This study indicates that children’s under the age group of 1- 3 years (80.9%) 
are mostly affected. 
2. Distribution according to sex:  
 Among 42 cases of study 39% were male children and 61.9% were female 
children.  
3. Distribution according to food factors: 
 Most of the Patients (55%) are non vegetarians, which is one of the important 
factors of the disease. 
4. Distribution of paruva kaalangal:  
 According to Paruvakaalam the highest Distribution (38%) was noted in 
Pinpani and 28.5% was noted in ilavenir kaalam. 
5. Distribution of lands:  
 Among the selected 42 cases 89% of them were from Marutham land and 4% 
of them were from Kurinji and. Incidence of disease in marutha nilam were due to 
altered life style and environment. The study was conducted in and around Tirunelveli 
which has all the 5 lands but majority patients came within limit of marutham land. 
6. Distribution according to Uyir thathukkal:  
i. Derangement of Vatham:  
Due to derangement of Vatham, the following symptoms may occur. Abhanan 
(95.23%) causes watery stools, Vyanan (4.76%) causes emaciation, Samanan (16.6%) 
causes loss of appetite and kirugaran (71.4%) causes cough, watery nasal discharge 
and sneezing. 
ii. Derangement of Pitham:  
  Analpitham was deranged in 95.23% of patients causing loss of appetite, 
indigestion, diarrhea and abdominal bloating, Ranjagam was deranged in 38.05% of 
patients due to anemia, saadhagam was deranged in 19.04% of patients causing 
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limitations in their daily physical activities, and presage was deranged in 12% of cases 
who were presented with fever, manifestation of skin.  
iii. Derangement of Kabam:  
  Due to derangement of Kabam, avalambagam was deranged in 95.23% of 
patients, kilethagam was deranged in 95.23% of patients causing watery nasal 
discharge, bothagam was deranged in 28.57% of patients and tharbagam was 
deranged in 71.42%. 
7. Distribution according to Ezhu Udar thathukkal:  
 In Ezhu udalthathukal 100% of the cases had derangement of Saaram (loss of 
appetite, indigestion, watery nasal discharge, drowsiness)  and 71% had derangement 
of Oon and koluppu (weight loss). 
8. Enn vagai thervugal:  
 According to this study, naa was affected in 76% of cases (Coated and pallor), 
Sparisam was affected in 71% of cases (Indigestion, fever), Mozhi was affected in 5% 
of patients due to congenital disorder, and Malam was altered in 95% of patients 
(diarrhea). 
9. Distribution according to Etiological factors:  
 From the above table it is evident that intake of poor hygiene, milk protein 
allergy, climate change are the main cause of Kana maantham. Antibiotic history also 
has an important role in causing AGE. Others mostly may be due to infectious cause. 
10. Distribution of clinical features:  
 Almost 95% cases were presented with diarrhea, 90% of cases had bloated 
abdomen, 28% of cases had fever, and 70% cases had watery nasal discharge. 
11. Bristol stool chart assessment: 
             In our clinical practice, we were strongly surprised by the facility and the 
great precision of the patients to report their stool form, meaning that they usually and 
daily verify these stools. 
 Type 7- Liquid consistency with no solid pieces indicates severe diarrhea 20 
cases had this type stool consistency. 
 Type 6- Mushy consistency with ragged edges indicates mild diarrhea 12 
cases had this type of stool consistency. 
 Type 5- Soft blobs with clear cut edges indicate fibre lacking diet 8 cases had 
this type of stool frequency. 
     Type 3- A sausage shape with cracks in the surface is normal stool but the 2 
cases have increased frequency max 5 times per day and hence treated with 
medication. 
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12. Relieved symptoms: 
     Diarrhea has been relieved in 50% of cases and bloated abdomen in 19% within 1-
2 days, maximum diarrhea case has been reduced within 3 days, bloating abdomen 
has been relieved in 60%, watery nasal discharge in 47.6% and diarrhea in 28.5% 
within 3-5 days Headache has reduced in 2.3% and there is no marked improvement 
in cough symptom it is reduced only in 4.7%. 
13. Dehydration assessment: 
                 Minimal dehydration (57%) is managed very effectively and easily, 
moderate dehydration(38%) is managed with help of panjamutty kanji, chukku mudi 
kanji and ORS if needed. Severe dehydrated (5%) patient is managed and supported 
with ORS and as moderate dehydration. 
14. Lab Investigation:  
 Routine examinations of blood, Urine and Motion were done during admission 
and discharged if necessary and the patient is willing. There are no marked variations 
in lab investigation few cases had low Hb value one of the case has increase in Hb 
after treatment. 
15. Biochemical analysis:  
 Qualitative analysis of the trial drug revealed the Presence of Ferrous iron 
which is more soluble and readily absorbable form that helps in treating children who 
are associated with Anemia. The study also indicates the presence of sulphate, starch, 
tannic acid, unsaturated compounds and reducing sugar.  
16. Antimicrobial activity:  
 Antimicrobial activity of uthamani karukku  is resistant to E.coli, 
Streptococcus and individual antimicrobial activity((Ramanathan R et al, 2013)  of  
uthamani  leaves are  resistant to E. coli and aqueous extract has sensitive at 125ul 
concentration. The herbs collected from the geographical area, preparation method, 
storage  has a lot of influence in the drug which may be altered due to climatic change 
and even any microbiological error or else truly the drug is not sensitive to the 
species. 
17. Pharmacological analysis:  
Anti diarrheal activity: 
 Pharmacological Analysis showed that the drug has significant anti diarrheal 
activity. Diarrhea is caused by four pathophysiologic processes: increased luminal 
osmolarity, electrolytes secretion, decreased electrolytes absorption, and abnormal 
intestinal motility causing reduction in intestinal transit time. Castor oil is used for 
induction of diarrhea as Ricinoleic acid initiates diarrhea via mechanisms such as 
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irritation of GI mucosa, leading to the release of prostaglandin which stimulates 
gastrointestinal motility and electrolyte secretion, reducing electrolyte absorption 
from the intestine and colon; these are similar to the pathophysiologic processes 
resulting in diarrhea. Therefore, the antidiarrheal activity of the plant might be due to 
the activities that oppose the actions of castor oil for induction of diarrhea or 
pathophysiologic processes leading to diarrhea. The extract has been shown to 
decrease the intestinal fluid accumulation. This suggests that the plant extract may 
decrease water and electrolyte secretion to the intestinal lumen while promoting their 
absorption, which in turn could decrease intestinal overload and distension, leading to 
a decrease in intestinal motility (giving a longer time for absorption) and water 
contents of the fecal drops and hence overall reduction in the total number of 
defecation instances and diarrheal drops in treated groups. This is consistent with the 
mechanism of action of loperamide for its antidiarrheal effect as presented in the 
literatures. In addition, the extract may have an anticholinergic activity and cause 
reduction in intestinal motility and secretion, which is in agreement with the action of 
atropine on the intestine 
Antipyretic activity: 
  In the antipyretic activity UK which could partly contribute to its ethno 
medical use. However, further investigation is required to isolate the active 
constituents responsible for these activities and to elucidate the exact mechanisms of 
action. 
Toxicity study: 
 All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. No signs of toxicity were observed 
in animals from different dose groups during the dosing period of 28 days. 
18. Selection of the Trial Drug:  
 The selection of trial drug is based on the Pharmacological action of drug and 
sastric evidences. 
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11. SUMMARY 
 The disease Kana maantham can be compared with Acute Gastro Enteritis as 
etiological factors, clinical features and the age criteria has apparent 
similarities. 
 Objective of the clinical trial is to evaluate the efficacy of the drug uthamani 
karukku towards the disease kana maantham, among various drug of choice 
for the disease kana maantham UK has its own unique way. 
 The adjuant of the drug is hot water and the medicine is in karukku form it 
does not contain any taste and administration is made simple to pediatric age 
group. 
 Kana maantham and its factors, AGE and the drugs are detailly reviewed.  
 Drug authentication and microbiological study report has been provided for 
the drug UK.  
 Pharmacological activity- antidiarrheal activity of UK has 60.44% compared 
with loperamide. 
 Inclusion and exclusion criteria are strictly followed to enroll the patients; 
siddha diagnostic methods are used to confirm the diagnosis in a well 
mannered way. 
 Among all the symptoms maximum number of children attained normalized 
stool consistency (Bristol scale ≤4) on day 2 and day 3.  
 Gastro intestinal symptoms have better improvement when compared with 
respiratory system, only symptom which has low percentage of recovery is 
cough. Uthamani has a main role in curing cough but when administered as 
karukku its prognosis rate is less. Other symptoms like watery nasal discharge 
has better prognosis. 
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12. CONCLUSION 
 
  The most common pediatric disease kana maantham, almost all the child will 
definitely experience. Medicine preparation of UK is cost effective and its 
administration is made easily. Future availability of the drugs, its safety and its action 
towards the disease kana maantham has satisfied well. 
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CASE REPORT FORM I- SCREENING 
(Selection of patient) 
 
1. Institution                :    Government Siddha Medical College,          
                                            Palayamkottai, Tamil Nadu. 
2. Name of the patient  : 
      3. Informant               :  
4. Op No\Ip No         :                             
5. Age (years)              :            
6. Gender                     :                      
7. Residential address   :
 …………………………………………………………….                
                
……………………………………………………………… 
            
8. Contact No.:   ……………………….. 
 
CRITERIA OF INCLUSION – Yes (1), No (0) 
 
9. Age between 01 to 12 years 
 
     10. Symptoms 
         10.1       Diarrhea 
 
 
10.2      Bloating abdomen 
 
 
10.3      Fever 
 
S.NO. 
xvi 
 
10.4   Watery Nasal discharge 
 
 
10.5   Cough 
 
10.6   Headache 
 
              10.7    Drowsiness 
 
 
              10.8   Weight loss 
             
CRITERIA FOR EXCLUSION – Yes (1), No (0) 
 
11. Age below 01 year and above 12 years 
 
12. Protein Energy Malnutrition 
 
13. Severe Dehydration 
 
         14. Tuberculosis 
 
15. Pneumonia 
 
16. Peritonitis 
 
The patient is eligible / not eligible for the study 
 
Date: 
Signature of the Investigator: 
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CASE REPORT FORM II - HISTORY 
 
 
1. Institution:  Government Siddha Medical College,   
                    Palayamkottai, Tamil Nadu. 
2. Name of the patient: ……………...…………….. 
3. Father/ Mother/ Guardian Name: ……………………… 
4. Address: 
…………………………………………………………. 
5. Age (years): …….. 
6. Gender:  Male                Female 
7. Fathers Occupation: 
(Unemployed 0, Desk work 1, Field work 2, Field work with physical 
laborer 3, Field with intellectual 4)  
8. Total Family members: ……. 
9. Income per capita per month (in Rs.): ……….. 
Chief complaint with duration (if any) in days  
( Absent (0), Present (1) )                                                                                                                            
Duration 
10. Diarrhea 
 
11. Bloating abdomen 
 
12.  Fever 
 
      13.       Watery Nasal discharge 
 
      14.        Cough 
 
 
 
 
S.NO. 
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14.      Headache 
 
 
15.      Drowsiness 
 
16.     Weight loss 
 
17.     Loss of appetite 
 
         19.     Other  
 
               If, yes specify: 
 
Personal History 
 
20. Diet   
(Vegetarian 0, Non - vegetarian 1, Lacto – vegetarian 2 and 
Mother feed 3 ) 
 
21. Mother feed 
    (Yes 0, No 1) 
 
22. Appetite 
     (Normal 0, low 1 and high 2) 
 
         23. Bowel opening 
               (Difficult 0 and Normal 1) 
 
         24. Pica  
               (No 0 and Yes 1) 
 
         25. Nail Biting  
              (No 0 and Yes 1) 
 
         26. Any other (specify) 
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Past Medical history  (No 0 and Yes 1) 
 
27. Anemia (iron deficiency, Sickle Cell, Thalessemia) 
 
28. Blood transfusions  
 
29. Measles 
 
30. Mumps 
 
31. Convulsions 
 
32. Meningitis 
 
33. Operations  
      If yes, what illness? 
 
34. Other serious medical illnesses 
      If yes, what kind? 
 
35. Is your child currently taking any medications?  
      If any, specify 
 
 
Family history 
 
36. Any Hereditary disease      
(No 0 and Yes 1) 
 
If, yes specify: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
 
Immunization history 
         
   37. Properly Immunized     
         (No 0 and Yes 1) 
 
PHYSICAL EXAMINATION: 
 
38. Height (cm)                      ………           
 
39. Weight (kg)                      ………   
 
40. Temperature (F0)              ……… 
 
41. Respiratory rate (/min)     ……… 
 
42. Heart rate (/min)               ………       
 
43. Blood pressure (mmHg)    ……… 
 
44. Dehydration  
                       
   Minimal/none                 mild/moderate                         severe            
 
(Degree of dehydration assessment according to WHO) 
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SYSTEMIC EXAMINATION: 
No abnormalities detected (NAD) (0) and abnormalities present (1) 
 
45. Digestive system  
If abnormal, details  
Inspection: 
 
 
 
 
Palpation: 
 
 
 
 
Percussion: 
 
 
 
 
Auscultation: 
 
 
 
 
46. Respiratory system 
If abnormal, details  
Inspection: 
 
 
 
 
Palpation: 
 
 
 
 
Percussion: 
 
 
 
Auscultation: 
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47. CVS   
  
If abnormal, details  
 
 
 
 
 
 
48. CNS 
 
If abnormal, details  
 
 
 
 
 
 
Date:                                                                Signature of Investigator 
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CASE REPORT FORM III-  INVESTIGATION  FORM 
 
1. Institution: Government Siddha Medical College, Playamkottai,      
                   Tamil Nadu. 
2. Name of the patient: ………………… 
3. Age (years): ….. 
 
4. Gender: Male                   Female 
 
5. Date of Assessment: 
 
6. Siddha diagnostic methods 
 
6.1 Nilam: 
       
 
       Kurinji                        Mullai                     Marutham                
 
       Neithal                        Paalai 
 
 
6.2 Kaalam: 
 
       Kaarkaalam                       Koothirkaalam  
 
        Munpanikaalam                  Pinpanikaalam                   
 
 Ilavenirkaalam                    Muthuvenirkaalam 
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6.3 Uyir thathukkal: 
  
Vatham:   (Normal 0, affected 1) 
                         Remarks 
 
Pranan 
 
 
Abhanan 
 
 
Vyanan 
 
 
Uthanan 
 
 
Samanan 
 
 
Naagan 
 
 
Koorman 
 
 
Kirugaran 
 
 
Devathathan 
 
 
Dhanajeyan 
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Pitham: ( Normal 0, Affected 1)                           Remarks 
 
Analam 
 
 
Ranjagam 
 
 
Saathagam 
 
 
Alosagam 
 
 
 
Prasagam 
 
 
Kabam: ( Normal 0, Affected 1)                        
                                                                      Remarks 
     
 
Avalambagam 
 
 
Kilethagam 
 
 
Pothagam 
 
 
Tharpagam 
 
 
Santhigam 
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6.4 Udalthathukal:     ( Normal 0, Affected 1)                                  
                                                     Remarks 
 
Saaram 
Senner 
Oon 
Kolupu 
Enbu 
Moolai 
Sukilam/ Suronitham 
 
6.5 EnvagaiThervugal: ( Normal 0, Affected 1) 
                                                Remarks 
  
Naadi 
 
 
Na 
 
 
Niram                       
 
 
 
Sparism                    
 
Mozhi 
 
 
Vizhi 
 
 
Malam    
 
 
Moothiram           
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7. Modern diagnostic methods 
 
7.1 Stool Examination: ( Normal 0, Affected 1)                        
 
Color  of  stool:   
Specify- 
 
 
Consistency: 
Specify- 
(Bristol stool chart) 
 
 
Presence of mucous:  (No 0, Yes 1) 
 
 
Presence of blood: (No 0, Yes 1) 
 
 
7.2 Urine Examination: 
 
Color   
(Straw color 0, Dark yellow 1, Red 2) 
 
  
  Urine output   
(Normal 0, Decreased 1, Minimal 2) 
 
  
7.3 Laboratory investigation  
 
 Blood   (If necessary and the patient is willing) 
 
 
Hb ……….gms%    
 
(Normal 0, Abnormal 1) 
 
Total count  ………. million/cu,mm 
(Normal 0, Abnormal 1) 
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Differential count    (Normal 0, Abnormal 1) 
     
        Neutrophils       %     
 
      
        Lymphocytes     % 
 
 
       Monocytes         % 
 
 
       Eosinophils        % 
 
      
       ESR      mm(1/2 hr)   
 
                    Mm(1 hr) 
      (Normal 0, Abnormal 1) 
 
      Serum electrolytes    
 
Urine Investigation: (If necessary and the patient is willing) 
 
Alb  
 
Sug  
 
Dep 
 
Stool Examination: (If necessary and the patient is willing) 
 
Ova  
 
Cyst 
 
Occult blood  
 
Culture 
 
 
 Date:                                                          Signature of Investigator: 
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After intake of medicine for the pediatric disorder kana maantham 
 
 
1. Institution: Government Siddha Medical College, Playamkottai,  
                   Tamil  Nadu. 
2. Name of the patient:  
3. Age( years): 
4. Gender: Male                   Female 
 
5. Name of the medicine 
 
 
6. Date of commencement of treatment: 
 
 
7. Date of cessation of treatment: 
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Investigation table. After intake for kana maantham disease. 
 
AT 
No. of visits BT 1 2 3 
Date of visits     
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SUMMARY AND FINDINGS 
 
 
 
 
 
 
 
 
 
 
IP FORM DAILY REVIEW: 
 
DAY 1 
 
 
 
DAY2 
 
 
 
DAY3 
 
 
 
DAY4 
 
 
 
DAY5 
 
 
 
DAY6   
 
 
 
DAY7 
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FORM IV 
GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPT. OF KUZHANTHAI MARUTHUVAM 
                  CONSENT FORM 
An open clinical study to evaluate the safety and efficacy of Siddha sastric 
Formulation “Uthamani karukku” for the management “Kana maantham” 
CERTIFICATE BY INVESTIGATOR 
I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent. 
Date ……………….      Signature………….. 
place ……………….     Name ……………… 
  
xxxiii 
 
CONSENT OF INFORMANT 
I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my Son / Daughter body functions. 
I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
My name or my son/ daughter name will not be mentioned in any of the trial is 
assured by the physician. 
I am, exercising my free power of choice; hereby give my consent to be included as a 
subject in the clinical trial of “Uthamani karukku” for the management “Kana maantham” 
       Informant Signature:………. 
Date:       Informant Name: …………. 
Place:       Patient Name:………………. 
Signature of Witness    Relationship:………………… 
!
!
! !
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Ofibitqbqe<!ohx<Oxiiqe<!yh<Hkz<!hcul<< < < < < << < < < < << < < < < <!
!
!!!!!!Gpf<jkbqe<!!ohbi<!!!!!!!!!!!!!!!!!!!!!ohx<Oxii<!!Ngqb!fie<!we<!Sb!
fqjeUme<! hijtbr<Ogim<jmbqz<! dt<t! nvS! sqk<k! lVk<Kug<! gz<Z~iqbqz<!
fmk<kh<hMl<! Gpf<jkgtqe<! g{lif<kl<! we<El<! Nb<Ug<G! sl<lkl<! ntqh<hjk!
okiquqk<K!wPkqg<!ogiMg<Gl<!yh<Hkz<!hcul</!
Olx<hc! kjzh<jhg<! ogi{<m! Nb<U! fqi<{bl<! sl<hf<klie! gQp<! Gxqh<hqmh<hm<Mt<t!
lVk<Kuiqeiz<!Olx<ogit<th<hMl<!-u<!Nb<Ug<G!dme<!hMukx<G!we<!Sb!fqjeUme<!
LP! yh<HkjzBl<! okiquqk<Kg<! ogit<gqOxe</! -f<k! Nb<uqe<! Ofig<gl<?! Nb<Uosb<Bl<!
Ljx?! dmx<! hiqOsikje?! lVk<Kul<! osb<Bl<! Ljx?! okimi<! g{<gi{qh<H!
we<heux<Xme<! Ofib<! fqi<{bk<jk! lkqh<hqMux<gigUl<! fmk<kh<hMl<! Nb<U%mh<!
hiqOsikjegt<! hx<xqb! uqiquie! uqtg<gl<?! weK! Gpf<jkjb! hiQm<sqk<K! lVk<Kul<!
osb<Bl<!lVk<Ku!nZuziqeiz<!uqtg<gh<hm<me/!OlZl<!-u<!Nb<uqzqVf<K!wf<OfvLl<!
wu<uqk! giv{r<gTl<! okiquqg<giK! we<eiz<! uqzg! LcBl<! we<hjkBl<! fie<! fe<G!
nxqOue</!
weK!Gpf<jk!nz<zK! weK! ohbjvObi! lVk<Kuiqe<!Nb<U! Hk<kgk<kqz<! outqbqm!
lim<mii<gt<! we<hjkBl<! fie<! fe<G! nxqOue</! -u<! Nb<ju! Olx<ogit<Tl<!
lVk<Kuiqeiz<! weg<G! upr<gh<hm<m! Ofibiti<! kguz<! kitqje! LPjlbig! nxqf<K!
ogi{<mKme<! weK! sf<Okgr<gjt! LPjlbig! -u<! Nb<ju! Olx<ogit<Tl<!
lVk<Kuiqml<! Ogm<M! nxqf<K! ogi{<Ome</! nke<! hqe<ei<! biVjmb! fqi<hf<kLl<! -e<xq!
we<! osif<k! uqVh<HmEl<! SbfqjeUmEl<! -u<! Nb<Ug<gie! yh<Hkjzk<! okiquqk<Kg<!
ogit<gqe<Oxe</!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ! -h<hcg<G!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Ofibitqbqe<!ohx<Oxii<!jgobih<hl<!
ohbi<;!
Lguiq;!
!
!
Okkq;!
!
sim<sqbqe<!ohbi<;!
Okkq;!
sim<sqbqe<!jgobih<hl<;!
!
Nb<UlVk<Kui<!jgobih<hl<;!
Okkq;!
!
Olx<hii<jubiti<!jgobih<hl<;!
Okkq;  
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FORM IVB 
GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAI, POST GRADUATE DEPARTMENT OF  
KUZHANTHAI MARUTHUVAM 
 
A CLINICAL STUDY ON “KANA MANTHAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS MAANTHA CHOORANAM 
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….         Gender:  …………..   Date of Enrollment: …… 
Date of Completion :……….          Informant: …………. Reliability :  …………… 
FORM IVB – WITHDRAWAL 
Date of Trial commencement  : 
Date of withdrawal from trial  : 
Reason (s) for withdrawal   : Yes /No 
Long absence at reporting   : Yes /No 
Irregular treatment    : Yes /No 
Shift of locality    : Yes /No 
Complication adverse reactions if any: Yes /No 
Exacerbation of symptoms   : Yes /No 
Pt. not willing to continue  : Yes /No 
Date : 
 
 
Signature of Guide:           Signature of Principal Investigator:  
      Signature of HOD: 
 
  
xxxvi 
 
FORM IV-C 
PATIENT INFORMATION SHEET 
Name of the principal investigator: ……………………………………… 
Name of the institution :  GOVERNMENT SIDDHA MEDICAL  
        COLLEGE&HOSPITAL, Palayamkottai 
 
Information sheet for patients participating in the open clinical trial 
I, _____________________________________ Studying as PG Scholar at  
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI  is doing a trail on the study “VIDA MANTHAM” (Childhood 
Asthma). It is a most common  disease in children. In this regard, I am in a need to ask you 
few questions. I will maintain confidentially of your comments and data obtained. There will 
be no risk of disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No compensation 
will be paid to you for taking part in this study.  
You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions.  
If you agree your child to be a participate in this study, he/she will be included in the 
study primarily by signing the concern form and then you will be given the internal medicine 
“MAANTHA CHOORANAM  (500mg)  3 to 10days. Twice a day. 
 
Date : 
 
Signature of Guide:             Signature of Principal Investigator:  
 
 
     Signature of HOD: 
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FORM IV D 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
A CLINICAL STUDY ON “kana maantham”-A PEDIATRIC DISORDER AND THE 
DRUG OF CHOICE IS uthamani karukku 
FORM IVD- DIETARY ADVICE FORM 
S.I.No: ………….       OP/IP No: ………   Name: …………............... 
Age: …………….         Gender:  ………    Date of Enrollment: …………. 
Date of Completion :……….     Informant: ………….   Reliability :  …………..... 
 
The following diet to be taken: The following food should be 
avoided 
 Leafy green vegetables 
 Ponnaganni keerai, 
manathakkali keerai, siru 
keerai, mulai keerai 
 whole grains 
 Cereals 
 Seasonal friuts 
 Panjamutti kanji 
 Jeera water 
 Chukka mudi kanji 
  Soaked Nuts 
 
 White sugar 
 Maitha products( bakery 
foods) 
 chocolates 
 Bottled Milk 
 Canned Juices and cool 
drinks 
 Avoid oily & Spicy foods. 
 Refined oil and palm oil 
 Frequent intake of egg  
 Mushroom 
 
 
 
 
Date: 
Station:       Signature of the Investigator: 
 
Signature of the Guide :         Signature of the HOD 
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FORM IV E -NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
Reporting form for suspected adverse reactions to Siddha Drugs 
 
Please Note:  i. All Consumers/Patients and reporters information will remain  
          confidential.  
  ii. It is requested to report all suspected reactions to the concerned,  
                            even if it does not have complete data, as soon as possible.  
 
Peripheral centre code :    State : 
Name  
 
Father Name  
 
Patient record no 
Ethnicity  
 
Occupation  
Address 
 
Village/Town 
Post/Via 
District /State 
Date of Birth/Age 
Sex:Male /Female 
Weight: 
Degam: 
 
2. Description of the suspected adverse reactions please complete boxes below 
Date and time of initial 
observation  
 Season: 
Description of reaction   Geographical area: 
 
  
xxxix 
 
3. List of all medicines/Formulations including drugs of other systems used by the 
patient during the reporting period:  
Medicine Daily 
dose 
Route of 
administration  
Vehicle – 
Adjuvant 
Date Diagnosis for 
which medicine 
taken Starting Stopped 
Siddha       
Any 
other 
system of 
medicines  
     
 
 4. Brief details of the Siddha Medicine which seems to be toxic : 
1)Details Drug – 1 Drug – 2 Drug 3 
a) Name of the 
Medicine  
   
b) Manufacturing unit 
and batch no. and 
date 
   
c) Expiry date    
d) Purchased and 
obtained from 
   
e) Composition of the 
formulation / part of 
the drug used 
   
  
2) Dietary restrictions if any 
3) Whether the drug is consumed under institutionally qualified medical 
    supervision or used as self medication  
4) Any other relevant information  
5. Treatment provided for adverse reaction: 
 
  
xl 
 
6. The result of the adverse reaction /side effect / untoward effects ( Please complete the 
boxes below )  
Recovered Not 
recovered: 
 
Unknown Fatal If fatal 
Date of death: 
Severe  
Yes /No 
Reaction abated after drug stopped or dose reduced 
  
Reaction reappeared after re introduction : 
 
 
 
Wash the patient admitted to hospital? If 
yes, give name and address of hospital  
 
 
7. Any laboratory investigation done to evaluate other possibilities? If yes specify: 
 
8. Whether the patient is suffering with any chronic disorders? 
 
Hepatic   Rental  Cardiac Diabetes Malnutrition  
 
Any Others  
9. H/O previous allergies /Drug reactions: 
 
10. Other illness (please describe): 
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Type (please tick):Nurse/Doctor/Pharmacist/Health 
worker/Patient/Attendant/Manufacturer/ Distribution /Supplier /Any other    (please 
Specify) 
Name : 
Address 
Telephone /E-mail if any: 
 
 
Signature of the reporter      Date : 
 
 
 
 
Please send the completed form to  
 TO:       FROM: 
Government Siddha Medical College 
& Hospital, Palayamkottai, Post 
Graduate Department of Kuzhanthai 
Maruthuvam 
 
  
The co-ordinator, 
Pharmacovigilance Department, 
Govt., Siddha Medical College 
and Hospital, 
Palayamkottai,  Tirunelveli. 
 
xlii 
 
This Filled- in ADR report may be send within one month of observation / occurrence of 
ADR 
 
 
 
 
 
 
 
 
 
 
 
 
Date : 
 
Station: 
 
Signature of Investigator: 
 
 
Signature of Guide:     Signature of HOD  
 
 
 
 
 
 
 
Who can report?  
 Any health care professionals like Siddha Doctors 
/Nurses /Siddha Pharmacists / Patients Etc.,   
What to report? 
 All reactions, Drug interactions 
Confidentiality  
 The patient’s identify will be held in strict confidence 
and protected to the fullest extent 
 
